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1
Introduction
1.1 Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive, neurodegenerative brain disorder and the most
common form of dementia, accounting for 50 % of the cases. The disease involves progressive
cognitive and functional impairment, starting with inability to remember recently learned
facts and eventually the inability to carry out the simplest tasks [1]. The main risk factor
for AD is age, with its incidence doubling every 5 years after the age of 65. It is at this age
when most people is diagnosed with AD, however early-onset, familial AD can occur much
earlier, although it represents 5% of the cases [2]. More than 35 million people suﬀer from
AD worldwide, and it is predicted to aﬀect 1 in 85 people by 2050 [3]. The economic and
social cost of AD is very high. Therefore, as our world population ages, the cure for AD has
become one of the challenges of this century.
AD is named after Dr. Alois Alzheimer, a German psychiatrist that identiﬁed the ﬁrst case
in 1901. A woman patient had an unusual behavior with her symptoms including memory
loss, language problems and unpredictable behavior. Her conditioned worsened and in 1906
she died. Dr. Alzheimer examined her brain and noticed great neuronal loss together with
abnormal extracellular protein clumps (now referred as amyloid plaques) and intracellular
tangled bungles of protein ﬁbrils (currently denoted neuroﬁbrillary tangles) [4]. Neuronal
loss, amyloid plaques and neuroﬁbrillary tangles are currently considered the three main
hallmarks of AD.
It was not until the 80s that a signiﬁcant eﬀort towards the understanding of the molecular
mechanisms of AD was made. Analysis of the extracellular amyloid deposits revealed that its
major component was a short peptide named amyloid-β (Aβ) [5]. Intracellular neuroﬁbrillary
tangles were also found to be mainly composed of the protein tau, a microtubule-stabilizing
protein, abnormally hyperphosphorylated [6]. These two ﬁndings prompted two approaches
into studying the causative eﬀect of Alzheimer’s disease: the amyloid hypothesis [7] and
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the tau hypothesis [8], postulating Aβ or tau as the fundamental causative agent in AD.
After several years of research, it is currently accepted that the neurotoxic eﬀect of tau is
downstream to the eﬀect of Aβ [9]. However, it is also known that tau is necessary for
neuronal loss to take place [10, 11].
1.2 Aβ production
Figure 1.1: Schematic represenation of the formation and aggregation of the Aβ peptide to-
gether with the two other hallmarks of Alzheimer’s disease: neuronal death and neuroﬁbril-
lary tangles of hyperphosphorylated tau (left side of the ﬁgure). The picture shows as well the
non-amyloidogenic processing of APP (right side of the ﬁgure). The image is a courtesy from
the National Institute of Health (http://www.nia.nih.gov/alzheimers/scientiﬁc-images).
Aβ is a peptide obtained from a membrane protein, the amyloid precursor protein (APP)
(Figure 1.1). Although the function of APP is not clearly deﬁned, it has been proposed to be
involved in neuronal development [12] or in a disputed iron-transport function [13, 14]. APP
can be cleaved by two diﬀerent pathways. The non-amyloidogenic pathway involves α- and
γ-secretases, yielding the Amyloid precursor protein Intracellular Cytoplasmatic/C-terminal
Domain (AICD) peptide. In the amyloidogenic pathway APP is sequentially cleaved by β-
and γ-secretases, resulting in the production of the Aβ peptide. γ-secretase cleavage is not
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speciﬁc, and a variety of Aβ peptides are formed, ranging from 38 up to 43 amino acids. The
most abundantly produced Aβ variant is the one with 40 amino acids, Aβ40, while the most
related to neurotoxicity and cognitive defects associated to AD is the one with 42 amino
acids, Aβ42 [15, 16]. The ratio between Aβ40 and Aβ42 is a biomarker used in AD [17].
Moreover, Aβ42 is the most abundant variant found in amyloid plaques [18]. Both AICD
and Aβ are produced throughout our lives. However, in AD Aβ accumulates either because
of an excessive production or a defective clearance. Aβ self-assembles into intermediate
oligomeric species that evolve into protoﬁbrils, that ﬁnally self-assemble into amyloid ﬁbrils,
the main component of amyloid plaques (Figure 1.2). Amyloid ﬁbrils present three main
hallmarks [19, 20]: 1) they have a characteristic appearance under analysis in an electron
microscope, 2) they are identiﬁed by apple-green birefringence when stained with the dye
Congo Red and seen under polarized light and 3) they present a typical diﬀraction pattern,
accounting for a beta pleated sheet conformation, with the direction of the polypeptide
backbone perpendicular to the ﬁbril axis, what is called a cross-β structure.
Researchers in Japan discovered a glutamate deletion in Aβ E22Δ-Aβ [21]. This peptide
variant was reported to form Aβ oligomers but not ﬁbrils, a signiﬁcant fact that appealed
the scientiﬁc community to further investigate this peptide. However, later reports showed
that E22Δ-Aβ42 aggregated into ﬁbrils as well [22, 23, 24].
Figure 1.2: Schematic representation of Aβ aggregation. Aβ monomers self-assemble to form
low-molecular weight (LMW) oligomers that further aggregate into protoﬁbrils that ﬁnally
evolve to amyloid ﬁbrils.
1.3 The amyloid hypothesis
Since amyloid ﬁbrils are the main component of amyloid plaques and Aβ is a natural product
present in the brains and cerebrospinal ﬂuid (CSF) of humans throughout life, amyloid ﬁbrils
were ﬁrst proposed to be the main causative agents in AD [25]. However, subsequent studies
found a lack of correlation between amyloid plaque load and severity of the disease [26],
while the soluble pool of Aβ correlated much better with neurotoxicity [27]. For this reason,
there was a shift in the amyloid hypothesis: the main causative agents were thought to be
the intermediate soluble species in the aggregation of Aβ the so-called Aβ oligomers [28].
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A lot of experimental evidence, coming from in vitro studies, genetic analysis and the use
of mice models, supports the amyloid-β oligomer hypothesis (see review [29] and references
therein). Evidence include:
1. APP gene is located in chromosome 21 and AD-like pathology is invariably observed
in Down syndrome.
2. Synthetic Aβ peptides are toxic to hippocampal neurons both in vitro and in vivo.
3. Mutations in the APP gene ﬂanking or inserted in the Aβ region alter the amount of
Aβ produced and/or the Aβ aggregation properties. These mutations are involved in
the development of early-onset AD.
4. Inherited mutations in the presenilin genes (encoding the β- and γ-secretases) increase
the Aβ42:Aβ40 ratio causing early and aggressive forms of AD.
5. In humans, the ApoE 4 allele is a major genetic risk factor to develop late-onset
AD and when human ApoE is expressed in mice lacking endogenous ApoE, ﬁbrillar
deposits are observed.
6. Transgenic mice with human APP show a time-dependent increase in Aβ and develop
behavioral and neuropathological changes equivalent to those observed in AD.
7. Injection of synthetic Aβ into the brains of tau transgenic mice or co-expression of
mutant APP with mutant tau accelerates tau hyperphosphorylation and leads to the
formation of neuroﬁbrillary tangles similar to those characterizing AD in humans.
1.4 Aβ oligomers: isolation and characterization
In order to tackle AD, important eﬀorts have been made to isolate the species responsible for
neurotoxicity. Relevant work comes from the isolation of in vivo-derived oligomers. Naturally
secreted oligomers of Aβ from cultured cells were found to inhibit hippocampal long-term
potentiation (LTP), which is an electrophyisiological parameter related to memory [30].
Another contribution came from the group of Karen Ashe [31]. They were able to isolate an
Aβ oligomer (a dodecamer, named Aβ*56) from the brain of transgenic mice modeling to AD-
type pathology. Isolated Aβ*56 disrupted memory when administered to young rats. Work
from Dennis Selkoe’s laboratory showed that Aβ dimers extracted from cerebral cortexes of
AD patients impaired synaptic plasticity and LTP in hippocampal neurons [32].
Although the work on in vivo-derived oligomers has been signiﬁcant, these are not well char-
acterized due to sample limitations. Most of the studies characterize the order of natives
oligomers using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
with the limitations and artifacts this technique might have [33]. The fact that oligomers
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survive the extraction protocol has lead some authors to postulate that these oligomers are
covalently cross-linked [34]. However, recentwork from these same authors have suggested
that they are an SDS artifact [35]. Besides, toxicity might not rely on just one deﬁned
oligomeric species, but on a group of them or on the process of aggregation itself [36, 37].
In order to obtain further structural information on soluble Aβ intermediates, there has been
a great eﬀort devoted to the preparation of Aβ oligomers in vitro. Protoﬁbrils were isolated
using size-exclusion chromatography. They are short, curvilinear species of around 200 nm
length and shown to be toxic against cultured cells [38]. A combination of synthetic Aβ42
and cell culture media yields an oligomeric preparation called Amyloid-Derived Diﬀusible
Ligands (ADDLs) [39]. They are a mixture of Aβ aggregates, mainly composed of spherical
species of 5-6 nm size. ADDLs were found to be toxic against hippocampal culture cells,
and they have been extensively used to model Aβ oligomers both in vitro and in vivo. Other
Aβ oligomers preparations were obtained by stabilizing oligomers using detergents. In this
context, Preglobulomers and Globulomers are oligomers derived from the incubation of Aβ42
aggregates with SDS [40, 41]. Preglobulomers are spherical aggregates of 1-2 nm size and a
molecular weight of 16/20 kDa. Globulomers are larger, having a molecular weight of 38/42
kDa and 4-5 nm size. Globulomers were found to block LTP in vitro.
1.5 The quest for structural characterization of Aβ ag-
gregation
In spite of the eﬀorts to stabilize Aβ oligomers in vitro, characterizing them with the available
biophysical techniques have proven diﬃcult due to their heterogeneous and dynamic nature.
A wide variety of techniques have been used to characterize Aβ aggregates (Figure 1.3). The
Thioﬂavin T (ThT) binding assay [42] is widely used to quantify the amount of amyloid ﬁb-
rils in solution. ThT is the chloride salt of a cation (ThT+) that consists of an N-methylated
benzothiazole fragment linked to a dimethylaniline ring. ThT+ binds to amyloid ﬁbrils via
two main stabilizing mechanisms [43]: a π–π interaction between the dimethylaniline moiety
and the peptide backbone and the CH–π interaction between a Gly residue and the benzoth-
iazole moiety. This second interaction inﬂuences ThT ﬂuorescence properties and depends
on the amino acid residues of the peptide chain. Although its use is limited to the end
product of Aβ aggregation, the knowledge of the interaction of Aβ and ThT has enabled the
development of powerful imaging agents in AD [44]. X-ray diﬀraction yields accurate inter-
and intramolecular distance in ﬁbrils and can be used as well to conﬁrm its cross-β struc-
ture [45]. Transmission Electron Microscopy (TEM) or Atomic Force Microscopy (AFM)
enable characterizing the morphology of aggregates. However, its usefulness is limited by
the size of the aggregates (they must be large enough) and by the ability of these aggre-
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gates to deposit on the surface analyzed. In combination with solid-state Nuclear Magnetic
Resonance (ssNMR), extremely detailed structural information of amyloid ﬁbrils has been
obtained [46]. Furthermore, Robert Tycko’s laboratory have shown polymorphic structures
of Aβ ﬁbrils [47] and recently they have been able to obtain 3D structures of Aβ ﬁbrils
derived from brains of actual AD patients [48]. Hydrogen/Deuterium Exchange (HDX) ex-
periments have also been used to map the regions of the Aβ peptide in amyloid ﬁbrils present
in the core of the ﬁbril or being part of a ﬂexible and/or exposed region. It is notable the
pioneering work by the Ronald Wetzel group in ﬁbrils [49] and protoﬁbrils [50, 51] of Aβ40.
The group of Roland Riek made a major contribution by deriving a 3D structure of Aβ42
ﬁbrils [52] when studying a series of Aβ42 mutants using HDX experiments analyzed by
NMR.
Important eﬀorts have also been devoted to the characterization of earlier stages of ag-
gregation. An oligomer was isolated and their structure proposed in an AFM study [53].
When combining several techniques, high-resolution structures of oligomers have been ob-
tained: Using EM and X-ray crystallization, David Eisenberg and coworkers were able to
characterize a deﬁned type of oligomer of a peptide segment of αB-crystallin, what they
called cylindrins [54]. Based on this structure, they proposed a model for Aβ. The group
of Yoshitaka Ishii, using EM and ssNMR, derived the structure of a β-sheet rich Aβ in-
termediate [55]. Solution NMR is a high-resolution technique yielding extremely detailed
structural information on proteins and their kinetics. In fact, it has been used to determine
the exchange kinetics of Aβ aggregation between monomer and oligomer [56] and monomer
to protoﬁbril [57]. Up to date, no Aβ oligomer has been characterized using solution NMR
though. However, this technique is not applicable to the study of high-order aggregates
as their relaxation properties hamper their detection. Another common technique used
to study soluble Aβ aggregates, Dynamic Light Scattering (DLS), determines the hydro-
dynamic radius (the size) of the diﬀerent species in solution and allows quantiﬁcation of
aggregates according to their size. However, large ﬁbrillar aggregates cannot be detected
quantitatively [58]. Other state-of-the-art techniques have given very valuable information
on oligomer structure: Ion mobility coupled to mass spectrometry (IM-MS) gives detailed
information on the size and number of subunits of an oligomer present in solution [59], hav-
ing the ability to preserve the solution structure in the gas phase. This technique facilitates
detection of deﬁned Aβ oligomers: Michael Bowers’ work stressed the relevance of tetramers
and dodecamers in Aβ aggregation [60] as well as the possibility to monitor the inﬂuence
that Aβ40 has in Aβ42 aggregation and vice-versa [61]. Aβ aggregates such as amyloid
ﬁbrils have not been successfully characterized by MS most likely due to diﬃculties in ion-
izing them and/or their non-homogeneous nature. Single molecule ﬂuorescence techniques
also allow to obtain information with regards to the order of an aggregate but its applica-
bility is limited to low-molecular weight aggregates. Using this technique, it was possible to
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characterize the order of diﬀerent Aβ soluble intermediates in solution together with their
interactions with non-covalent complexes of Aβ with another protein, clusterin [62]. Other
techniques, such as circular dichroism (CD) or Fourier Transformed Infrared Spectroscopy
(FT-IR) [63] can be conﬁdently used throughout the full process of aggregation and they
give information about secondary structure. In fact, application of an improvement of tradi-
tional FT-IR, Attenuated Total Reﬂection FT-IR, enabled the distinction of diﬀerent types
of oligomers [64]. However, both CD and FT-IR are not able to distinguis between diﬀerent
species coexisting in solution, since they are averaging techniques. Moreover, in the case of
FT-IR the concentration of protein needs to be very high and the use of buﬀers is restricted.
Figure 1.3: Several techniques can be used to characterize Aβ aggregates. To detect, char-
acterize and quantify the diﬀerent species populating Aβ aggregation we have used PL-HDX
experiments.
In order to detect, quantify and characterize the diﬀerent species formed during Aβ aggrega-
tion, we used a pulse-labeling hydrogen/deuterium exchange (PL-HDX) strategy [65]. This
part of my work is described in Chapter 3 of this thesis.
1.6 Therapeutics for AD
Even though the mechanism of action of Aβ and even the causative agent of AD is still a
matter of debate, much work has been done to pursue the cure of this devastating disease.
Currently there are only four drugs marketed against AD, and all of them only provide
symptomatic alleviation: Donepezil, Rivastigmine and Galantamine are three cholinesterase
inhibitors. The mechanism of action of these drugs consists on enhancing the cholinergic
transmission in neurons thus yielding moderate improvement on cognition, behaviour, and
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functional and global clinical state in AD patients [66]. Memantine has also beneﬁcial eﬀects
on AD patients, and it acts by antagonizing N-Methyl-D-Aspartate (NMDA) receptor [67].
However, none of these drugs are disease-modifying, so the need for a cure for AD is today
necessary and urgent.
In order to treat AD several approaches have been taken, and several cellular mechanisms
have been targeted [68]. To modulate Aβ production inhibitors of β- and γ-secretases as
well as γ-secretase modulators (GSAM) have been developed. Rosiglitazone, a β-secretase in-
hibitor was discontinued at phase III in 2010 and tarenﬂurbil and semagacestat, two GSAMs,
were discontinued at phase III in 2009. Currently, CHF-507, a small molecule, a GSAM,
is in Phase II from 2011 [69]. To target Aβ aggregates, a great eﬀort has been devoted to
immunotherapy: antibodies with the ability to disrupt amyloid plaques or capture Aβ such
as solaneuzumab and bapineuzumab, reached Phase III clinical trials, but were eventually
discontinued. The scientiﬁc community met the failure of these two antibodies with disap-
pointment, since they were entirely designed to target the disease according to the amyloid
hypothesis. Even though some criticism on the hypothesis raised, it still holds valid to the
community [70]. The immunotherapeutic approach to AD still holds an aﬃtope, AD-2,
in Phase II clinical trials [71]. Moreover, some small molecules exhibiting anti-aggregation
activity have reached advanced clinical trials. The most notorious case was tramiprosate,
that reached phase III clinical trials but failed to show a real eﬀect and was discontinued
in 2007. Currently, epigallocatechin gallate, a polyphenol isolated from the leaves of the
green tea, is in phase III against AD and exhibits anti-aggregation as well as antioxidant
activity. Exebryl-1 is a small molecule reducing amyloid load, currently in phase I [72], and
PBT-2 is a molecule inhibiting Aβ aggregation together with a chelating activity in Phase
II [73]. Most of the compounds described in this paragraph are reviewed in a work from
Mangialashce et al. [74] and references therein.
In order to further understand the mechanism of action of the compounds showing anti-
aggregation activity, there has been plenty of in vitro studies in which the eﬀect of several
small molecules have been tested in Aβ aggregation. The use of conformation-speciﬁc an-
tibodies, such as A11, an antibody targeting oligomeric but not ﬁbrillar amyloid [75], or
OC, an antibody targeting ﬁbrillar and protoﬁbrillar assemblies [76], allowed to identify and
classify small molecule mechanism of action in Aβ aggregation: Diallyltartardiamide, orange
G, chicago sky blue 6B, direct red 80 and apigenin were found to inhibit Aβ ﬁbrillization
by stabilizing oligomers [77], while 2,2’-dihydroxybenzophenone, juglone [77] and methylene
blue [78] were found to inhibit oligomer formation but not ﬁbrillization. Studies using a
combination of biophysical techniques, such as the ThT binding assay, TEM and MTT as-
says, showed that entacapone, currently marketed against Parkinson’s disease, inhibited Aβ
ﬁbrillization and rescued toxicity in PC12 cells [79]. Similarly, salvianolic acid B was found
to inhibit Aβ aggregation together with a neuroprotective eﬀect on SH-SY5Y cells [80] and
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tramiprosate, formerly in clinical trials, showed as well promising anti-aggregation activity in
vitro [81]. Tetracycline, a widely used antibiotic, also inhibited Aβ aggregation and rescued
neurotoxicity in N2a cells and the mechanism of action proposed consisted on the stabiliza-
tion of a deﬁned oligomeric species [82]. Stabilizing non-toxic oligomers was also found to be
the mechanism of action of riluzole [83], scyllo-inositol, formerly in clinical trials [84, 85, 86]
and epigallocatechin gallate [87, 88], currently in clinical trials. Other small molecules act
on AD toxicity by chelating metals, such as Cu2+, Zn2+ or Fe2+, but have also been shown to
inhibit Aβ aggreationon. This is the case of clioquinol [89] and ammonium tetrathiomolyb-
date [90]. Other compounds showing potential in inhibiting Aβ aggregation are peptides.
They oﬀer the possibility of ﬁne-tuning the inhibitory activity due to their aﬃnity for Aβ.
Several works have shown in vitro the potential of these molecules, although their in vivo
application is still limited [91]. Of special interest are a group of peptides derived from the
same sequence as Aβ found to inhibit Aβ aggregation and exhibiting neuroprotective eﬀects
on cell cultures, such as the C-terminal fragments (CTFs) [92] or inrD, a peptide developed
in our laboratory [93].
In spite of all the eﬀorts in ﬁnding molecules that modulate Aβ aggregation, there is still
a signiﬁcant lack of information in deﬁning the type of Aβ aggregate they stabilize. By
applying the PL-HDX strategy we aim at contributing to a better understanding of the
mechanism of action of molecules that interfere with Aβ aggregation.

2
Objectives
The objectives we posed for my thesis were the following:
1. Detect, characterize and quantify the diﬀerent aggregates formed during Aβ aggrega-
tion for three Aβ variants with diﬀerent roles in Alzheimer’s disease: Aβ40, Aβ42 and
E22Δ-Aβ42.
2. Determine the neurotoxicity associated to each of the detected Aβ aggregates.
3. Monitor the eﬀect of small molecules and a peptide on the diﬀerent aggregates detected
during Aβ42 aggregation.
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Aβ aggregation
3.1 Results
3.1.1 Characterization of Aβ aggregation by conventional meth-
ods
As stated in the objectives of this thesis (Chapter 2), we worked with three diﬀerent Aβ
variants: Aβ40, Aβ42 and E22Δ-Aβ42. The reason for this choice is due to Aβ40 being the
Aβ variant most abundantly produced, Aβ42 the most associated with AD and E22Δ-Aβ42
was described, at the beginning of our work, to form oligomers but not amyloid ﬁbrils (see
Introduction, section 1.2).
In order to study the aggregation of Aβ using the PL-HDX experiment analyzed by Electro-
spray Ionization-Mass Spectrometry (ESI-MS), Aβ variants were aggregated at 25◦C in MS
compatible buﬀer conditions, such as 50 mM NH4OAc, 1 mM Tris · HCl and 0.01% NaN3,
pH 7.4. We ﬁrst monitored the process by using conventional methods. We monitored the
aggregation by the ThT binding assay [42], an assay that quantiﬁes amyloid ﬁbrils (Figure
3.1).
Aβ40 showed a lag phase of 13 days and a plateau of maximum ﬂuorescence at 19 days of
aggregation, indicating that after 19 days most of the peptide was in ﬁbrillar form. The
behavior for Aβ42 was diﬀerent, showing a lag phase of 6 days and the plateau of maximum
ﬂuorescence was reached after 9 days. The behavior of E22Δ-Aβ42 did not follow the
typical sigmoidal curve: there was no lag phase and the ﬂuorescence increased throughout
the aggregation experiment.
Next, we monitored the aggregation of the Aβ variants by Transmission Electron Microscopy
(TEM). Negative-stain TEM allowed us to study the diﬀerent morphologies of Aβ aggregates
at diﬀerent times during aggregation (Figure 3.2). In agreement with ThT results, Aβ40
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Figure 3.1: The ThT binding assay monitors Aβ ﬁbril content. (A) Aβ40 showed a lag phase
of 13 days and after 19 days Aβ40 was aggregated into amyloid ﬁbrils. (B) Aβ42 exhibited 6
days of lag phase and reached the plateau of ﬂuorescence at 9 days. (C) E22Δ-Aβ42 showed
a non-conventional behavior, without lag phase and constant increase in ThT ﬂuorescence.
Figure 3.2: Aβ aggregation monitored using negative-stain TEM. A) Aβ40 showed protoﬁb-
rillar aggregates at early stages, while it formed ﬁbrils after 13 days. B) In Aβ42, protoﬁbrils
were observed at intermediate aggregation time points(5-7 days), signiﬁcantly diﬀerent from
the ﬁbrils observed at later stages (9-11 days). C) E22Δ-Aβ42 aggregated very fast and
showed ﬁbrillar material from the initial stages of aggregation (scale bar: 100 nm).
ﬁbrils were observed later than those of Aβ42. Aβ40 required 17 days to form well-deﬁned
ﬁbrils, whereas Aβ42 required 9 days of aggregation. It is also signiﬁcant to notice that both
Aβ40 and Aβ42 aggregation showed protoﬁbrillar intermediates (short, curvilinear, small
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ﬁlaments of around 200 nm) at 9 and 5-7 days, respectively. In the case of E22Δ-Aβ42, we
observed protoﬁbrils as well as ﬁbrils from the earliest aggregation time points; after 2 days
of aggregation, most of the peptide was in ﬁbrillar form.
Fibrils formed by each of the diﬀerent Aβ variants were further characterized using X-ray
ﬁber diﬀraction. Although we experienced diﬃculties in preparing aligned ﬁbrils, we could
obtain diﬀraction patterns for the intramolecular distance between β-strands as well as the
intermolecular distance between consecutive strands by plotting the azimuthal plots (Figure
3.3). In the case of Aβ40 and Aβ42 we obtained identical values: 10.4 and 4.7 A˚, respectively,
while for E22Δ-Aβ42 the intramolecular distance diﬀerred: it was found to be shorter: 10.1
A˚. Although there are no reported values in the literature for E22Δ-Aβ42, E22Δ-Aβ40
intermolecular distances were found to be signiﬁcantly shorter: 9.4 A˚ [22].
Figure 3.3: Characterization of Aβ ﬁbrils. The ﬁbrils were not aligned, but they showed
their reﬂections in (A) Aβ40, (B) Aβ42 and (C) E22Δ-Aβ42. (D) One-dimensional azimuthal
plots, showing intensity as a function of D spacing for Aβ40 (blue), Aβ42 (red) and E22Δ-
Aβ42 (green).
3.1.2 Optimization of MS experiments to analyze PL-HDX sam-
ples
Both ThT binding assay or TEM studies gave us relevant information with regards to Aβ
aggregation. However, the ThT binding assay is not able to distinguish between diﬀerent
species populating Aβ aggregation, as it is only able to interact with amyloid ﬁbrils. Electron
microscopy distinguishes between morphologies, being most useful in characterizing high-
molecular weight aggregates ﬁbrils, but does not give detailed information on diﬀerent low-
molecular weight aggregates. Moreover, its applicability is determined by the ability of
a determined species to deposit on the copper grid. X-ray ﬁber diﬀraction, as its names
implies, gives structural information on the end-products of the aggregation –the ﬁbrils. For
this reason we moved to a technique that might give relevant structural information with
regards to the diﬀerent species populating Aβ aggregation.
The PL-HDX-ESI-MS experiment is based on the solvent accessibility of amide hydrogens.
Aβ aggregation is started in a protonated buﬀer and at a given time of aggregation Δtagg,
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the solution is exchanged to a deuterated buﬀer for a short, ﬁxed, labeling time Δtlabel.
This pulse of exchange is chosen so that amide protons located in unprotected (unstruc-
tured) regions of the aggregates undergo isotope exchange, while amide protons located in
protected (structured) regions are retained. To quench the exchange, the sample is freeze-
dried. To analyze the deuterium incorporation in the aggregates, these will be dissociated
into monomers by transfer to a dimethyl sulfoxide (DMSO) solution, able to preserve the
deuteration content [94], and analyzed by ESI-MS (Figure 3.4). MS has the unique ability to
detect and characterize populations of molecules with diﬀerent degrees of exchange, thus en-
abling the detection of the diﬀerent species present at a given aggregation time. Therefore,
this methodology has the potential to detect and characterize the transient and dynamic
intermediate species populating Aβ aggregation.
Desalting methodology
Previous work in our laboratory involving HDX-MS was performed directly infusing the
DMSO solution into the mass spectrometer, using disposable needles as a source of nano-
ESI and providing an inert atmosphere in the infusion chamber [95]. This methodology
was used to study molecular recycling in amyloid ﬁbrils [96] and involved a previous step
of ultracentrifugation, so that all the buﬀer was removed and only the pellet containing the
proteic material was analyzed by MS. The ultracentrifugation step, apart from allowing the
separation of amyloid ﬁbrils from soluble Aβ species involved as well the virtually complete
elimination of salts that may interfere with ESI.
In our case, HDX was quenched by lyophilization, thus the salts were not eliminated. Al-
though NH4OAc is a volatile salt, Tris · HCl and NaN3 are not, and they may interfere with
ESI-MS spectra giving undesirable adduct peaks. For this reason we decided to include a de-
salting step prior to the infusion of our sample into the mass spectrometer (see Materials and
Methods). This step consisted of the transport of the peptide sample with aqueous buﬀer
to a C8 column, where desalting took place for 1 min at 50 μL/min. Following the product
speciﬁcations, 10 column volumes were needed for a complete desalting, and 1 minute at 50
μL/min was enought to ensure a complete desalting. The sample was then eluted with ace-
tonitrile (ACN)-based solution into the mass spectrometer for detection. Since the sample
to be injected was dissolved in DMSO, we substituted all the PEEKR© material by the more
resistant TeﬂonR©, including tubing, ﬁttings and the two valves needed for the desalting step.
Moreover, in order to minimize the back exchange in the desalting step, the system was kept
at low temperature using ice to cool the solvents and the valve system.
Once we had the experimental design for the ESI-MS analysis, we optimized the working
conditions. We performed the optimization experiments with the Aβ40 peptide dissolved
at 50 μM in the DMSO-based buﬀer (composition described in the Materials and Methods
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Figure 3.4: Schematic representation of the PL-HDX-ESI-MS exchange experiment. (A) The
experiment starts by incubating soluble protein under aggregation conditions in a protonated
buﬀer. After a variable aggregation time, Δtagg, labeling takes place for a ﬁxed period,
Δtlabel, using deuterated buﬀer. The magnitude of Δtlabel is chosen so that only unprotected
amide protons will signiﬁcantly exchange with the solvent. After the labeling pulse, freeze-
drying is used to quench exchange. Diﬀerent samples are prepared at deﬁned Δtagg values,
which are later solubilized into monomers by transfer to a DMSO solution and analyzed
by ESI-MS. The ﬁgures depict hypothetical scenarios in which Aβ is left to aggregate for a
short Δtagg (B) or a long Δtagg (C).
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section of this chapter). We found out that increasing from 2 to 4 kV the capillary voltage
and keeping the standard 100 V of sample cone, highly reduced the amount of DMSO and
dichloroacetic adducts on Aβ40 peaks (Figure 3.5).
Figure 3.5: Complete MS spectra for Aβ40 are shown at 2000 V, 3000 V and 4000 V of
capillary voltage at constant 100 V of sample cone. An inset of the +4 charge state is shown
in which adduct content is decreased as capillary voltage is increased.
Preserving HDX information during PL-HDX experiments
An important feature when performing HDX experiments is minimizing exchange during
experimental manipulation. There is the possibility to incorporate additional deuterium
atoms due to exchange with the solubilizing agent (Forward Exchange) and the possibility
of losing incorporated deuterium due to exchange with hydrogens of atmospheric water or the
hygroscopic nature of the solvent (Back Exchange). Controls for forward and back exchange
were prepared and analyzed as described in the Materials and Methods section.
Additional controls were carried out to establish that HDX information was preserved during
PL-HDX sample preparation. We dissolved monomeric Aβ40 at 30 μMin protonated buﬀer
(50 mM NH4OAc, 1 mM Tris · HCl and 0.01% NaN3, pH 7.4) and we diluted the sample 1/10
with D2O. After 10 seconds of exchange, we froze the sample in liquid N2 and lyophilized
it. Afterwards, we dissolved it in the DMSO-based buﬀer and analyzed it by ESI-MS. We
expected that all backbone amides of monomeric Aβ40 had exchanged to deuterons during
the labeling pulse and therefore obtained m/z values comparable to those for back exchange
controls. However, we obtained a m/z value lower than that for the back exchange control
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(see Materials and Methods in this chapter for the control preparation), which meant that
throughout the PL-HDX experiment, the deuterium content in Aβ was not preserved (Figure
3.6B). When we analyzed by MS Aβ40 after exchange but without the lyophilization step we
obtained m/z values identical to those for back exchange; this meant that in the lyophilization
step a high amount of back exchange was occurring (Figure 3.6C). For this reason we did not
lyophilize the sample but used a centrifugal evaporator, and this contributed to minimizing
back exchange (Figure 3.6D). However, when we performed the PL-HDX experiment and
we lyophilized the exchanged Aβ40 peptide “alone”, that is, being the only sample in the
lyophilizer, we were able to obtain an m/z value comparable to the back exchange control.
This meant that inside the lyophilizer there is HDX occurring from the diﬀerent samples
being processed. From then on, we performed our experiments lyophilizing in our own
lyophilizer, thus avoiding any water interference coming from other samples.
Figure 3.6: Keeping deuterium content in Aβ samples: (A)
Aβ40 back exchange control (B) Deuterated Aβ40 after
lyophilization dissolved in the DMSO-based buﬀer. (C)
Aβ40 after HDX. (D) Deuterated Aβ40 analyzed after cen-
trifugal evaporation dissolved in the DMSO-based buﬀer.
(E) Deuterated Aβ40 after isolated lyophilization dissolved
in the DMSO-based buﬀer. (F) Aβ40 forward exchange con-
trol. The blue and red bars indicate the m/z corresponding
to the forward and back control respectively.
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3.1.3 Characterization of Aβ aggregation by PL-HDX-ESI-MS over-
comes the heterogeneity of the process
We applied the PL-HDX-ESI-MS methodology to characterize the diﬀerent species popu-
lating Aβ aggregation for Aβ40 (Figure 3.7), Aβ42 (Figure 3.8) and E22Δ-Aβ42 (Figure
3.9). In the three cases the MS spectra follow a similar pattern: at the earlier time points,
Aβ has higher mass while at the end of the aggregation, the spectra correspond to peptide
with lower mass. This is consistent with the fact that Aβ is at ﬁrst in a low aggregated
form, having more exposed amide protons available to exchange to deuterons, while after
several days of aggregation Aβ forms higher order aggregates, those adopting more compact
structures and thus having less exposed amides available to HDX.
In order to obtain more information from the PL-HDX experiment, we globally adjusted the
mass spectra obtained for each Aβ variant to a combination of gaussian curves in collabora-
tion with Dr. Sergio Madurga, from the University of Barcelona (for a detailed explanation
of the ﬁtting see Materials and Methods). Each gaussian curve represents a diﬀerent species
present during Aβ aggregation. For each Aβ variant, all the MS spectra (triplicates for each
timepoint) were adjusted to a speciﬁc number number of gaussians: 3 in the case of Aβ40
and Aβ42, and 2 for E22Δ-Aβ42.
Aβ40
When the PL-HDX-ESI-MS experiment was used to study the aggregation of Aβ40, three
diﬀerent species were detected by ESI-MS (Figure 3.7). The ﬁrst species detected corre-
sponded in mass to the protein with all backbone amides exposed (37.4 ± 0.5, in red),
suggesting that it might include monomer and/or aggregates giving no protection against
HDX.Besides, the relative population of this species gradually decreased from 0 days to 17
days. This species was named early aggregates (EAAβ40). The second species detected cor-
responded to average masses indicative of 25.1 ± 1.0 amides (in cyan). Based on the peak
width, this was the most heterogeneous species formed during aggregation when compared
to the other two detected (Figure 3.7C), and its presence was constant being maximal at
13 days of aggregation. Combining this information with the TEM results (Figure 3.2),
this species was assigned to protoﬁbrils of Aβ40 (PFAβ40). The last species detected cor-
responded to average masses that indicated the presence of 13.5 ± 0.6 exposed amides (in
ochre). Because these species appeared toward the end of the aggregation and its population
signiﬁcantly correlated with the ThT signal and the observations of well-deﬁned ﬁbrils by
TEM, we attributed these species to ﬁbrils, FAβ40 [49].
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Figure 3.7: PL-HDX results analyzed by ESI-MS for Aβ40. (A) The MS spectra show the
relative populations of the species detected: EAAβ40 (red), PFAβ40 (cyan) and FAβ40 (ochre).
(B) Population percentage of each detected species as a function of Δtagg. (C) Number of
exposed amides for each detected species. (D) Peak width for each detected species.
Aβ42
The aggregation of Aβ42 was also studied by means of the PL-HDX-ESI-MS strategy (Figure
3.8). Three species were detected for Aβ42 aggregation, the same as for Aβ40. However,
our experiments showed that the nature of some of the species detected were diﬀerent for
both peptides. The number of exposed amides detected for the ﬁrst species detected (32.8
± 0.8, in green) was signiﬁcantly lower than what we would expect if all the amide protons
of monomeric Aβ42 were exposed to the solvent (41). We named them EAAβ42. These
results are consistent with the higher tendency of Aβ42 to aggregate. Similarly to Aβ40,
the majoritary species at intermediate Δtagg, with 23.6 ± 1.8 exposed amides, was the
most heterogeneous species detected (in blue) (Figure 3.8C) and its presence was constant
throughout the aggregation being maximal at 7 days. This species were less aggregated than
ﬁbrils. Electron microscopy images clearly show abundant protoﬁbrils (short, curvilinear
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Figure 3.8: PL-HDX-ESI-MS results for Aβ42. (A) The MS spectra show the relative
populations of the three species detected: EAAβ42 (green), PFAβ42 (blue) and FAβ42 (orange).
(B) Population percentage of each detected species as a function of Δtagg. (C) Number of
exposed amides for each detected species. (D) Peak width for each detected species.
aggregates of 200 nm) when the amount of this species is maximal (at 7 days). These
observations pointed to this species as being protoﬁbrils, PFAβ42. This assumption can be
corroborated taking into account other work in the bibliography: in 2006, it was found
that the HDX protection of isolated protoﬁbrils [51] was 26 ± 2 (for Aβ40), which closely
resembles the values obtained in our experiments. The last detected species corresponded in
mass to species presenting 14.8 ± 0.7 exposed amides (in orange). This species were assigned
to ﬁbrils, FAβ42 [52], and its relative population signiﬁcantly correlated with the ThT signal.
E22Δ-Aβ42
The PL-HDX-ESI-MS experiment was applied as well to the study of E22Δ-Aβ42 (Figure
3.9). Two diﬀerent species were detected. The most abundant species at early aggregation
times corresponded to an aggregate showing higher protection than monomeric E22Δ-Aβ42
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Figure 3.9: PL-HDX-ESI-MS results for E22Δ-Aβ42. (A) The MS spectra show the relative
populations of the two species detected: PFE22Δ-Aβ42 (violet) and FE22Δ-Aβ42 (turquoise).
(B) Population percentage of each detected species as a function of Δtagg. (C) Number of
exposed amides for each detected species. (D) Peak width for each detected species.
(30.8 ± 0.3). EM results described before(Figure 3.2C) showed the presence of abundant
protoﬁbrils and we named it PFE22Δ-Aβ42. The relative amount of PFE22Δ-Aβ42 immediately
decreases after the initial stages of aggregation, while the later aggregates, E22Δ-Aβ42
ﬁbrillar (FE22Δ-Aβ42) population concomitantly increases. All together, these experiments
provide further evidence of the extremely higher tendency of this peptide to aggregate.
3.1.4 Setup of a primary neuronal viability assay to study Aβ
neurotoxicity
The previous section showed the ability of the PL-HDX-ESI-MS strategy to “dissect” the dif-
ferent species populating Aβ aggregation. Once we were able to detect these aggregates, we
aimed at assigning the contribution of any species to a given variable. Since Aβ is related to
the neurotoxicity observed in AD, we decided to test the neurotoxicity of Aβ aggregates (for
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experimental details, see Materials and Methods) in collaboration with Dr. Llu´ıs Pujadas,
Dr. Daniela Rossi and Prof. Eduardo Soriano from the University of Barcelona.
In order to measure the toxicity of the Aβ preparations, we decided to work with primary
neuronal cultures from mice hippocampus. The assay we used to monitor neurotoxicity was
the well-established, rapid, convenient, economical and widely used 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [97]. This assay is based on the cleavage
of MTT, a yellow tetrazolium salt, to form a soluble blue/violet formazan product by mi-
tochondrial enzymes. The amount of formazan produced is directly proportional to the
number of living, not dead cells, present during MTT exposure and can be quantiﬁed by an
absorbance plate reader.
To optimize the MTT conditions such as Aβ concentration and incubation time, we worked
with ADDLs. ADDLs are synthetically derived Aβ42 oligomers that have been widely used
to study Aβ oligomer neurotoxicity (see Introduction, section 1.4). We treated primary
neural cultures with ADDLs and its corresponding vehicles at an Aβ42 concentration of 3, 5
and 10 μM. Sampls were left incubating diﬀerent time before performing the MTT reaction:
4, 15 and 24 hours (Figure 3.10). ADDLs showed a dose-response eﬀect and the vehicle
some toxicity, a result consistent with previous reports [98]. Only after 24 h incubation the
toxicity of ADDLs was signiﬁcantly diﬀerent from the vehicle. As an additional control,
we tested the toxicity of our aggregating buﬀer. Since the buﬀer contains 0.01% NaN3 and
NH4OAc we wanted to ensure that the putative buﬀer toxicity would not be so high as to
hamper our measurements. We determined a good compromise between ability to observe
toxicity in ADDLs and low toxicity of its vehicle and our aggregating buﬀer when working
at a 5 μM Aβ concentration and incubating for 24 h.
3.1.5 PFs are the main responsible for neurotoxicity in primary
hippocampal neurons
Having established a protocol to assay the eﬀect of Aβ aggregates in neural cultures, we
tested the contribution of the diﬀerent Aβ species detected during aggregation to toxicity. To
establish the eﬀect of all the samples obtained at diﬀerent Δtagg in the same primary neuronal
culture, we ﬁrst determined the eﬀect of sample freezing and thawing on the structure of the
aggregates. We found that aggregates formed during ﬁbril formation retained their structure
after a freezing/thawing cicle (Figure 3.11).
We next treated primary hippocampal neuronal cultures with frozen and thawed aliquots of
the same samples that had been studied in the PL-HDX-ESI-MS experiment and measured
the percentage of neuronal survival by the MTT assay.
In the case of Aβ40, neuronal survival steadily decreased from 90% to a maximum toxicity of
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Figure 3.10: Optimization for the MTT assay using ADDLs. Viability in primary cultures
incubated (A) 4 hours, (B) 15 hours and (C) 24 hours after sample treatment previous to
the MTT reaction. 100 % viability is adjusted to NT (non-treated) cells. The aggregating
buﬀer (agg buﬀ) is composed of 50 mM NH4OAc, 1 mM Tris · HCl and 0.01% NaN3, pH 7.4.
65% at 17 days. Later aggregation time points showed less toxicity thus survival gradually
increased to 80% of viability at 24 days (Figure 3.12A). For a given Δtagg, we combined
the populations obtained by ESI-MS with the MTT results and then used a multi-linear
regression analysis to obtain the toxicity adscribed to each detected species (EAAβ40: 101 ±
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Figure 3.11: Freezing and thawing samples obtained at diﬀerent times of Aβ aggregation
retains the structure of the aggregates. ESI-MS mass spectra (+4 charge state) showing
the relative populations of species detected during Aβ42 aggregation at the indicated Δtagg
times for (A) samples that have not undergone freezing and thawing and (B) samples that
have undergone freezing and thawing previous to PL-HDX-ESI-MS experiments. Peaks
representing EA, PF and F are shown as green, blue and orange bands, respectively. Peak
intensities are normalized to the overall species population.
12, PFAβ40: 56 ± 13, FAβ40: 78 ± 7). PFAβ40 was the population most strongly associated
to neurotoxicity.
When the same experiment was carried out with the Aβ42 preparations, a similar pattern
to that of Aβ40 was observed although the relationship between PFAβ42 and neurotoxicity
was even more noticeable (Figure 3.12B). Earlier aggregation time points displayed higher
toxicity than for Aβ40 (exhibiting 80% viability at day 0) and the viability gradually de-
creased to 38% at 7 days (maximum toxicity). Then viability increased until reaching the
same value as at the beginning, 80% at 11 days. When combining the ESI-MS data with the
MTT results in a multi-linear regression analysis, the toxicity of each detected species was
found to be the following: EAAβ42: 74 ± 7, PFAβ42: 17 ± 10, FAβ42: 106 ± 12. Although the
relative ratios of PF during Aβ40 and Aβ42 aggregation are similar, PFAβ42 showed higher
neurotoxicity and higher correlation to the global toxicity observed.
For E22Δ-Aβ42 almost no toxicity was observed (Figure 3.12C), so we did not determine
the toxicity corresponding to the species populating the aggregation of E22Δ-Aβ42.
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Figure 3.12: Toxicity of Aβ was evaluated by the MTT assay. (A) Aβ40 showed a proﬁle
in which the earlier and later aggregation times were less toxic than the intermediates.
(B) The trend for Aβ42 was even clearer, pointing to PFs as the principal responsible
for neurotoxicity. (C) In the case of E22Δ-Aβ42 almost no toxicity was observed. Aβ
concentration was 5 μM. 100 % viability is adjusted to the vehicle (the ammonium acetate
buﬀer).
Population percentages of Aβ species are included below to help visualize the signiﬁcant
correlation between cell viability and PF abundance.
3.2 Discussion
With the PL-HDX-ESI-MS experiment we have been able to overcome the heterogeneity
of the process of Aβ aggregation. We have been able to detect, characterize and quantify
the diﬀerent species populating Aβ aggregation: three for Aβ40 and Aβ42, and two for
E22Δ-Aβ42.
Although the same number of species were detected for both Aβ40 and Aβ42, our data indi-
cates that there are structural diﬀerences. The diﬀerences in exposed amides in EAAβ40 and
EAAβ42 is consistent with early aggregates of Aβ40 being soluble monomer and/or unstruc-
tured and/or highly dynamic aggregates while those of Aβ42 comprising more structured
and/or less dynamic aggregates. Thus, the diﬀerent structure and/or dynamic properties
of the early aggregates formed by the two Aβ variants oﬀer an explanation for the higher
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tendency to aggregate of Aβ42 compared to Aβ40. Besides, there are diﬀerences between
PFAβ40 and PFAβ42, although their protection against HDX is very similar and consistent
with previously reported data [50]. In agreement with the general ﬁnding that Aβ42 is more
toxic than Aβ40 [15, 16], the toxicity of PFAβ42 was shown to be signiﬁcantly higher than
PFAβ40. The two extra amino acids confer Aβ42 a higher tendency to aggregate and form
diﬀerent species [99]. One possibility to explain diﬀerences in toxicity between PFAβ40 and
PFAβ42 could be that PFAβ42 have a higher fraction of hydrophobic side chains exposed to
the solvent than PFAβ40.
We showed PFs as the most toxic species populating Aβ aggregation. If Aβ toxicity is
exerted via cell membrane disruption by pore formation or any other mechanism [100], the
ability of PFAβ42 to disrupt the cell membrane would be higher than for PFAβ40. One
possible explanation could be due to the higher hydrophobicity of Aβ42 when compared
to Aβ40 and the diﬀerent aggregation behavior of the two peptides as explained above.
However, there are two studies claiming that toxicity is not linked to speciﬁc preﬁbrillar
aggregates but to the ability of these species to grow and undergo ﬁbril formation [36, 37].
The toxicity of a deﬁned species (be it oligomer/protoﬁbril or ﬁbril) was found to be lower
than this same species in contact with monomeric Aβ or both species together. The relative
population of protoﬁbrils as a function of aggregation time, as determined in our PL-HDX-
ESI-MS experiments, follows a gaussian distribution. During the ﬁrst half of the distribution,
protoﬁbrils coexist with early aggregates so toxicity might be mediated by the process of
protoﬁbril-early aggregate interactions. However, during the second half of the distribution
protoﬁbrils coexist mainly with ﬁbrils and toxicity is still observed. Thus, although our
results are not consistent with speciﬁc protoﬁbril-monomer/early aggregate interactions,
they would be consistent with protoﬁbrils exerting their neurotoxicity through maturation.
It is also important to take into account that the toxicity of protoﬁbrils is higher than
monomer and ﬁbrils [37] and these species have been proposed to be the main culprits of
Alzheimer’s disease [101].
The detection of three species with diﬀerent structure as well as their evolution as a function
of time is in agreement with the nucleated conformational conversion (NCC) mechanism
of amyloid formation [102]. NCC proposes that monomers and/or low structured early
aggregates, EA, progress to more structured protoﬁbrilar aggregates, PF, not yet locked
into rigid structure yet capable to evolve into rigid ﬁbrillar forms, F. Our results are also
in agreement with a recent work carried out using single molecule ﬂuorescence to study
the aggregation of α-synuclein [103]. The authors also identiﬁed structural rearrangements
during α-synuclein aggregation from initially formed oligomers to stable, more compact
proteinase-K-resistant oligomers that ultimately lead to ﬁbril formation. In agreement with
our results, the more compact oligomers were those found more damaging to cells.
An aspect that also must be taken into consideration is the behavior of E22Δ-Aβ42. Con-
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sistently with previous reports, this peptide aggregated very fast [24, 23, 22]. However, we
failed to reproduce the toxicity observed in previous reports. We attribute this to a diﬀerent
way to measure toxicity: in our MTT assays we show that Aβ ﬁbrils (either 40, 42 or E22Δ)
do not display much toxicity and In a similar experiment carried out by the Glockshuber
group, the Lactate Dehydrogenase (LDH) assay, [23] they observed toxicity for Aβ42 but
not for E22Δ-Aβ42. However, when determining E22Δ-Aβ42 toxicity with LTP measure-
ments [21] or by neurite length measurements [23], E22Δ-Aβ42 as well as Aβ42 displayed
signiﬁcant neurotoxic behavior.
To summarize, we have detected diﬀerent aggregates present during Aβ aggregation using the
PL-HDX-ESI-MS. The fact that aggregates formed during the process of aggregation show
diﬀerent protection against HDX indicates that each of them adopts diﬀerent structures
and therefore that during the process of Aβ aggregation structural rearrangements occur.
By carrying out parallel neurotoxicity experiments, we found that protoﬁbrils, formed as a
result of a structural rearrangement, were the most toxic species to neurons. Thus, our work
points to the establishment of the structural determinants of Aβ protoﬁbril neurotoxicity as
a critical step to develop eﬃcient therapeutic strategies against AD.
3.3 Materials and methods
All reagents were purchased in Sigma-Aldrich unless otherwise speciﬁed.
3.3.1 Preparation of Aβ samples for aggregation experiments
Aβ40, Aβ42 and E22Δ-Aβ42 peptides were synthesized and puriﬁed by Dr. James I. Elliott
at Yale University (New Haven, CT, USA). To obtain Aβ in its lowest aggregation state
we used Size Exclusion Chromatography (SEC) (Figure 3.13). Aβ was dissolved in 6.8 M
Gdn · SCN, sonicated for 5 min, diluted to 4 M Gdn · SCN at a 5 mg/mL Aβ concentration,
centrifuged at 10,000 g for 5 min, and passed through a 0.45-μm Millex ﬁlter. The resulting
solution was injected into a HiLoad Superdex 75 HR 16/60 column (GE Healthcare) pre-
viously equilibrated with 50 mM NH4OAc, 1 mM Tris · HCl and 0.01% NaN3, pH 7.4, and
eluted at a ﬂow rate of 1 mL/min. The system was kept at 4◦C.
The peak attributed to the lowest aggregation state of Aβ was collected, and its protein
concentration was determined by HPLC (Waters, MA, US) in a Waters 2695 HPLC system.
The column used was a C4 Symmetry column and the runs were performed at 60◦C (Figure
3.14). HPLC quantiﬁcation was carried out using a calibration curve generated from Aβ
solutions previously quantiﬁed by amino acid analysis.
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Figure 3.13: SEC chromatograms of (A) Aβ40 (in blue), (B) Aβ42 (in maroon) and (C)
E22Δ-Aβ42 (in green). The peak attributed to the lowest aggregation state eluted at around
83 mL.
The Aβ solution was then diluted to 30 μM and left to aggregate at room temperature.
Aliquots of the solutions were taken at Δtagg ranging from 0 to 24 days for Aβ40, from 0 to
11 days for Aβ42 and from 0 to 19 days for E22Δ-Aβ42 to carry out the assays described
below.
3.3.2 ThT binding assay
ThT analysis was performed by mixing 50 μL of the Aβ aggregating solutions withdrawn at
speciﬁc Δtagg times with 15 μL of 100 μL ThT and 35 μL of 142 mM Gly·OH at pH 8.3 in a
Hard Shell R© Thin Wall 96-well ﬂuorescence plate (Costar, NY, US). The ThT ﬂuorescence of
each sample was measured using a ﬂuorescence plate reader (FluoDia T70, Photal, Photon
Technology International, Japan) at excitation and emission wavelengths of 450 and 485 nm,
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Figure 3.14: Representative HPLC chromatograms of (A) Aβ40 (in blue), (B) Aβ42 (in
maroon) and (C) E22Δ-Aβ42 (in green). Notice that the retention time directly correlates
with the hydrophobicity of the Aβ peptide. The gradient used was 0-60% B (ACN, 0.036%
triﬂuoroacetic acid) in 20 minutes. Purity of the Aβ peptides was higher than 95%.
respectively. The samples were analyzed in triplicate and average ﬂuorescence values and
standard deviation plotted. The recorded kinetic traces were ﬁtted to a sigmoidal function
as described by the following equation:
F = F0 +
(Fmax − F0)
1 + exp((t− t0.5)/b) (3.1)
F is the ﬂuorescence intensity, t is time, t0.5 is the time to reach 50 % of maximal ﬂuorescence,
b is the slope, and Fmax and F0 values correspond to the maximum and minimum ﬂuorescence
intensities. Estimated lag-time is t0.5 − 2× b.
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3.3.3 Electron microscopy
TEM analysis was carried out with samples withdrawn from the aggregating solution at
diﬀerent Δtagg times. A 10-μL aliquot of the samples was applied to a 200-mesh carbon-
coated formvar copper grid (Electron Microscopy Sciences, US), previously glow-discharged
for 5 minutes. After 1 min, the grid was washed with 30 μL of water and negatively stained
by treatment with 30 μL of 2% uranyl acetate for 1 min. Samples were observed in a Tecnai
Spirit electron microscope (FEI, The Netherlands) equipped with a LaB6 cathode. Images
were acquired at 120 kV with a MegaView III CCD camera using Analysis software (Soft
imaging System).
3.3.4 X-ray diﬀraction
After Δtagg of 30 days for Aβ40, 17 days for Aβ42 and 24 days for E22Δ-Aβ42, 5-μL
drop of the aggregating solution were suspended between two glass rods with beeswax tips
approximately 1.5 mm apart. Before complete drying of the ﬁrst drop, sequential addition
of extra drops of 5 μL was performed twice. Finally, ﬁbrils were allowed to dry completely.
Fibril diﬀraction data were collected on a crystallography beam line at the Department
of Biochemistry at the University of Cambridge. Azimuthal plots from diﬀractions were
represented using ImageJ R©.
3.3.5 PL-HDX experiments
Triplicate aliquots of 50 μL were withdrawn from the aggregating Aβ solution at diﬀerent
Δtagg. The buﬀer was exchanged to D2O (Euriso-top, France) by means of a 1/10 dilution
with D2O. Afterwards, the sample was left to exchange for a ﬁxed labeling time, Δtlabel.
Under the aggregation conditions used, a Δtlabel of 10 s was found to be the minimum, con-
trollable time required to exchange all protons to deuterons in a monomeric Aβ40 sample.
After the Δtlabel, samples were freeze-dried to quench exchange in a Christ Alpha 1-2 LD
Freeze Dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Germany). The lyophiliza-
tion was carried out for 14 hours and 0.10 mbar were reached.
The experiments of centrifugal evaporation were carried out in a SPD SpeedVacR© (Ther-
moFisher Scientiﬁc Inc., NY, US).
3.3.6 HDX analyzed by ESI-MS
To analyze the deuterium content of the samples, lyophilized samples were transferred into
a solution of 95% dimethylsulfoxide-d6(DMSO-d6, Euriso-top, France)/5% D2O at pH* 4.6
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(adjusted with Dichloroacetic acid-d2) [104]. This buﬀer solubilizes the various aggregates
into monomers and its pH* (pH read) is adjusted to the minimum exchange rate so that it
preserves the deuterium content of the protein molecules [94].
The samples were dissolved at a 50 μM concentration in the DMSO-based buﬀer and im-
mediately injected into a C8 desalting column (Micro Trap 1 mm ID x 8 mm, Michrom
Bioresources Inc., Auburn, CA, US). To remove involatile salts and buﬀers from the sam-
ple solution, the C8 column was washed with aqueous acidic solution (H2O, 0.1% formic
acid(FA)) for 1 min at a ﬂow of 50 μL/min. To elute the peptide from the C8 desalting
column, a mixture of 80:20 ACN:H2O, 0.1% FA was used. To pump solvent A (H2O, 0.1%
FA) a Reagent Manager pump (Waters) was used, and to pump solvent B (80:20 ACN:H2O,
0.1% FA) a pump from an Acquity UPLC (Waters) was used. The sample was directly
infused at 50 μL/min into a Waters LCT mass spectrometer (Premier XE, Micromass MS)
with a modiﬁed ESI probe. A two-position/eight-port and a two-position/ten-port Teﬂon R©
valves (Valco Instruments Co. Inc. AG International, Switzerland) were used together with
Teﬂon R© tubing and ﬁttings (Teknokroma, Spain). A schematic representation of the desalt-
ing system is depicted in Figure 3.15.
Data were collected in positive ion, with an applied capillary voltage of 4 kV, a cone voltage
of 100 V, a capillary temperature of 20◦C, a gas desolvation ﬂow rate of 300 mL/min and a
cone gas value of 50 mL/min. The same dead time (3 min) was used for sample preparation
and parameter adjustment for all measurements. The spectra were analyzed using MassLynx
V4.1 (Waters). All mass spectra presented were averages of 25 scans (1 s per scan), Aβ peaks
(including +3, +4, and +5 charge states) were observed and the most abundant +4 charge
state was selected for analysis.
3.3.7 Global multigaussian ﬁtting of PL-HDX-ESI mass spectra
To establish the number of species detected during aggregation of Aβ40, Aβ42 and E22Δ-
Aβ42, triplicate mass spectra for all Δtagg studied were globally analyzed and ﬁtted to
Gaussian distributions.
To this end, a program with a predeﬁned number of Gaussians/species N (from 1 to 4) was
developed in C, a general purpose programming language, by Dr. Sergio Madurga at the
University of Barcelona. The script for the program is shown at the end of this Materials
and Methods section.
In this multigaussian ﬁtting program, the objective function was the sum of chi squares
corresponding to the functions of N Gaussians that ﬁtted each experimental spectra: a
total of 29 for Aβ40, 34 for Aβ42 and 33 for E22Δ-Aβ42. The ﬁtting procedure minimize
the objective function such that the position and width of the Gaussians was equivalent
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Figure 3.15: Schematic drawing of the desalting setup. The valves are depicted in (A) load,
(B) desalting and (C) elution positions. After sample injection and desalting on the trap
column, the protein sample is eluted directly into the ESI source of the mass spectrometer.
for all spectra while the weight of each Gaussian was optimized for each spectrum. This
procedure was performed using a 2N-dimensional simplex on the position and width of the
N Gaussians in combination with a non-linear least squares regression for each function of
N Gaussians to obtain the weight of each Gaussian. The amoeba algorithm was used to
carry out the simplex search while the mrqmin algorithm of Numerical Recipes [105] was
used to implement the Levenberg-Marquardt method for the non-linear regression. To start
the ﬁtting procedure, approximate values for the unknowns were required. The optimization
procedure was performed several times with diﬀerent initial values to ensure that the global
minimum was reached. The number of N Gaussians/species that best described a given
aggregation process was taken to be n when the relative error associated to the ﬁtting
described by n+1 Gaussians was less than 20%. Following this criterion we found that three
Gaussians/species were needed to characterize Aβ40 and Aβ42 aggregation, while E22Δ-
Aβ42 required two (Table 3.1). To estimate the error of the parameters, the global set of
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spectra was divided in three groups, taking in each group one of the replicates of each day.
For those days in which only duplicate samples were available, one of the groups missed the
information for that day. Three independent ﬁttings were performed with the three subsets
of spectra. The obtained dispersion of width and position of the Gaussian allowed estimating
the standard error for the position and the width. The estimation of the standard error of
the weight of each Gaussian was obtained from the global ﬁtting using the dispersion of
values among the replicates. From this ﬁt, we derived several parameters for each of the
species detected such as the homogeneous or heterogeneous nature, the number of exposed
amides, and the relative population as a function of time.
Aβ40
# gaussian error relative error
1 1,21E+11
2 5,76E+10 52,3
3 3,26E+10 43,4
4 2,77E+10 15,1
Aβ42
# gaussian error relative error
1 1,38E+10
2 5,73E+09 58,5
3 3,79E+09 33,8
4 3,58E+09 5,6
E22Δ-Aβ42
# gaussian error relative error
1 3,08E+10
2 1,90E+10 38,3
3 1,63E+10 14,2
4 1,56E+10 4,3
Table 3.1: The error comes from the calculation after adjusting all the spectra to a given
number of gaussians. The relative error is deﬁned as relative error =
error(i−1) − errori
error(i−1)
×
100 where errori corresponds to the error of and adjustment with “i” gaussians.
The homogeneous or heterogeneous nature of the species was determined through the peak
widths, width of the peak at half height, which were taken directly from the adjustment.
The number of exposed amides was obtained by applying the following equation:
number of exposed amides = m−MW − FE +BE (3.2)
whereby m is the measured average mass corresponding to each detected species using the
center of the gaussian peak determined from the ﬁtting; MW is the measured average
molecular weight of Aβ in H2O (MW = 4329.8 Da for Aβ40, MW = 4514.1 Da for Aβ42
and MW = 4384.9 Da for E22Δ-Aβ42); and FE and BE refer, respectively, to the forward
exchange and the back exchange controls. The FE refers to the additional incorporation of
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deuterium atoms due to exchange with the solubilizing solvent (95% DMSO−d6, 5% D2O
at pH* 4.6) and the BE refers to the loss of incorporated deuterium due to exchange with
hydrogens of atmospheric water as a result of the hygroscopic nature of DMSO, during
ionization itself, and the presence of H2O in the desalting system. To account for FE and
BE, we used the following correction method adapted from a previously reported one [106].
FE = m0% −MW (3.3)
BE = MW +N −m100% (3.4)
whereby m0% is the measured mass of fully protonated Aβ disolved in the DMSO-based
buﬀer at 50 μM and processed as with the HDX samples (injected to the MS after 3 minutes
of dissolution); m100% is the measured mass of fully deuterated Aβ prepared using the same
sample used in the FE control after 6 hours in the DMSO-based buﬀer; and N is the number of
labile amide groups (39, 41 and 40 for Aβ40, Aβ42 and E22Δ-Aβ42, respectively). Equation
3 gives a value of 3.2 for Aβ40, 2.8 for Aβ42 and 2.8 for E22Δ-Aβ42, meaning that roughly
three backbone amide protons had undergone FE. Application of equation 4 gives a value
of 11.8 for Aβ40, 11.5 for Aβ42 and 10.0 for E22Δ-Aβ42, meaning that approximately
eleven deuterons (out of 39, 41 and 40 for Aβ40, Aβ42 and E22Δ-Aβ42, respectively) had
undergone BE. These values were obtained by analyzing triplicate control samples for the
BE and FE.
The relative population of a species at a given Δtagg was obtained by dividing the area
of the peak representing that species by the sum of the areas of each of the other species
contributing at Δtagg.
Pi =
Ai
Ai + Aj + Ak
× 100 (3.5)
3.3.8 Toxicity assays
ADDLs preparation
ADDLs were prepared as described [107]. Brieﬂy, Aβ42 was dissolved in hexaﬂuoro-2-
propanol (HFIP) at 1 mg/mL concentration, aliquoted in low-binding Eppendorf tubes,
and then HFIP was removed by freeze-drying. An aliquot of Aβ42 was dissolved in anhy-
drous DMSO to 5 mM and further diluted with ice-cold Ham’s F-12 medium without phenol
red (PromoCell GmbH, Germany) to 100 μM. This solution was incubated at 4◦C for 24 h
and then centrifuged at 14000 g for 10 min. The Aβ42 concentration in the supernatant was
determined using Bradford assay and found to range between 60 and 100 mM. The peptide
solution was diluted to the desired concentrations for MTT assays.
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Primary neuronal cultures
Hippocampal neurons were obtained from E16 OF1 mouse embryos (Charles River Lab-
oratories, MT, US). Brieﬂy, brains were dissected in PBS containing 0.6% glucose, and
hippocampi were dissected out. After trypsin (Gibco, CA, US) and DNAse (Roche Diagnos-
tics, Switzerland) treatments, tissue pieces were dissociated by gentle sweeping. Cells were
then counted and seeded onto poly-D-lysine-coated dishes in Neurobasal medium containing
B27 supplement (Gibco).
Neuronal viability measurements
Primary hippocampal neurons were seeded at 3104 cells/well in 96-well plates (Costar, NY,
US) maintained for 72-96 hours and then treated with Aβ samples frozen and thawn ob-
tained at diﬀerent Δtagg (at ﬁnal concentrations of 3 μM and 5 μM) or the corresponding
volumes of vehicle (50 mM NH4OAc, 1 mM Tris · HCl and 0.01% NaN3, pH 7.4) as a con-
trol. After 24 hours at 37◦C, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) neuronal viability was determined using the (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay from Roche (Cell Proliferation Kit I). Neuronal
viability was expressed as percent of MTT absorbance in treated cells as compared to cog-
nate vehicle-treated cells, which was taken as 100%. The assay was quantiﬁed at 595-690
nm on an absorbance plate reader.
3.3.9 Summary of statistical analysis
GraphPad Prism was used for all statistical analyses. The data are presented as mean ±
s.d. The images shown are representative of those obtained in at least three independent
experiments.
3.3.10 C-script for multigaussian ﬁtting
/* Programa per Fitting simultani d’experiments */
#include <stdio.h>
#include <math.h>
#define NRANSI
#include "nr.h"
#include "nrutil.h"
#include <string.h>
#define NPTMAX 1200
#define DIESMAX 40
#define NumGauss 4
#define MA 3*NumGauss
#define SPREAD 0.001
48 CHAPTER 3. Aβ AGGREGATION
#define MP 9 /* nombre de punts per amoeba MP=NP+1 */
#define NP 8 /* Nombre de dimensions per amoeba */
#define FTOL 1.0e-6
#define PI 3.14159265358979323846
float fit2gauss(float xcenters[6+1]);
float fit3gauss(float xcenters[6+1]);
float fit4gauss(float xcenters[8+1]); /* fit4gauss amb format inicial */
void fgauss2(float x, float a[], float *y, float dyda[], int na);
void fgauss3(float x, float a[], float *y, float dyda[], int na);
void fgauss4(float x, float a[], float *y, float dyda[], int na);
float fitexperimentsMult(float xcenters[8+1]); /* CANVI a versio ANTERIOR */
void proc1(void);
//float func(float x[])
//{
// return 0.6-exp(SQR(x[1]-0.5)+SQR(x[2]-0.6)+SQR(x[3]-0.7));
//}
float mz[NPTMAX+1],intensity[DIESMAX+1][NPTMAX+1];
float yb0_ini[DIESMAX+1],A1_ini[DIESMAX+1],xc1_ini[DIESMAX+1],w1_ini[DIESMAX+1];
float A2_ini[DIESMAX+1],xc2_ini[DIESMAX+1],w2_ini[DIESMAX+1];
float A3_ini[DIESMAX+1],xc3_ini[DIESMAX+1],w3_ini[DIESMAX+1];
float A4_ini[DIESMAX+1],xc4_ini[DIESMAX+1],w4_ini[DIESMAX+1];
float pa1_ini[DIESMAX+1],pa2_ini[DIESMAX+1],pa3_ini[DIESMAX+1],pa4_ini[DIESMAX+1];
float pw1_ini[DIESMAX+1],pw2_ini[DIESMAX+1],pw3_ini[DIESMAX+1],pw4_ini[DIESMAX+1];
float chiq_min,chiqdies_min[DIESMAX+1];
float xc1_min[DIESMAX+1],xc2_min[DIESMAX+1],xc3_min[DIESMAX+1],xc4_min[DIESMAX+1];
float pa1_min[DIESMAX+1],pa2_min[DIESMAX+1],pa3_min[DIESMAX+1],pa4_min[DIESMAX+1];
float pw1_min[DIESMAX+1],pw2_min[DIESMAX+1],pw3_min[DIESMAX+1],pw4_min[DIESMAX+1],
yb0_min[DIESMAX+1];
float yb0[DIESMAX+1],A1[DIESMAX+1],xc1[DIESMAX+1],w1[DIESMAX+1];
float A2[DIESMAX+1],xc2[DIESMAX+1],w2[DIESMAX+1];
float A3[DIESMAX+1],xc3[DIESMAX+1],w3[DIESMAX+1];
float A4[DIESMAX+1],xc4[DIESMAX+1],w4[DIESMAX+1];
float pa1[DIESMAX+1],pa2[DIESMAX+1],pa3[DIESMAX+1],pa4[DIESMAX+1];
float pw1[DIESMAX+1],pw2[DIESMAX+1],pw3[DIESMAX+1],pw4[DIESMAX+1];
float yres[NPTMAX+1];
int fit_g1,fit_g2,fit_g3,fit_g4;
int fix[20];
int NCALC;
int NoNegs;
int NPT,DIES;
int main(void)
{
float xcenters[8+1];
long idum=(-917);
float chi_primerfit;
float fdelta;
FILE *fpdades;
char filexyzinicial[200];
char comentari[500];
int i,nfunc,j,ndim=NP;
float *y,**p;
float ygauss1,ygauss2,ygauss3,ygauss4;
int diestot,opt[DIESMAX],index[DIESMAX],jj;
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int punt_xc1,punt_xc2,punt_xc3,punt_xc4;
char nom[100][100];
float valintensity;
strcpy(filexyzinicial,"Ab.fit.input");
fpdades = fopen(filexyzinicial,"r");
if (fpdades == NULL)
{ printf("Error al abrir el archivo %s\n",filexyzinicial);
return (1); }
fgets(comentari,200,fpdades);
fscanf(fpdades,"%d %d",&diestot,&NPT);
if(NPT>NPTMAX) { printf("ERROR NPT > NPTMAX\n"); exit(1); }
printf("Total series: %d\n",diestot);
printf("Noms: ");
for(i=1;i<=diestot;i++)
{
fscanf(fpdades,"%s",nom[i]);
printf("%s ",nom[i]);
}
printf("\n");
DIES=0;
for(i=1;i<=diestot;i++)
{
fscanf(fpdades,"%d",&opt[i]);
printf("%d ",opt[i]);
if(opt[i]==1)
{
DIES++;
index[DIES]=i;
}
}
printf("\nTotal Experiments a Analitzar: %d\n",DIES);
fscanf(fpdades,"%f %f %d",&xc1_ini[1],&w1_ini[1],&fit_g1);
fscanf(fpdades,"%f %f %d",&xc2_ini[1],&w2_ini[1],&fit_g2);
fscanf(fpdades,"%f %f %d",&xc3_ini[1],&w3_ini[1],&fit_g3);
fscanf(fpdades,"%f %f %d",&xc4_ini[1],&w4_ini[1],&fit_g4);
printf(" xc w \n");
printf("Pic1: %f %f fit: %d\n",xc1_ini[1],w1_ini[1],fit_g1);
printf("Pic2: %f %f fit: %d\n",xc2_ini[1],w2_ini[1],fit_g2);
printf("Pic3: %f %f fit: %d\n",xc3_ini[1],w3_ini[1],fit_g3);
printf("Pic4: %f %f fit: %d\n",xc4_ini[1],w4_ini[1],fit_g4);
for(j=1;j<=DIES;j++)
{ xc1_ini[j]=xc1_ini[1];
xc2_ini[j]=xc2_ini[1];
xc3_ini[j]=xc3_ini[1];
xc4_ini[j]=xc4_ini[1];
w1_ini[j]=w1_ini[1];
w2_ini[j]=w2_ini[1];
w3_ini[j]=w3_ini[1];
w4_ini[j]=w4_ini[1];
}
/* Lectura de les dades */
strcpy(filexyzinicial,"Ab.fit.data");
fpdades = fopen(filexyzinicial,"r");
if (fpdades == NULL)
{ printf("Error al abrir el archivo %s\n",filexyzinicial);
return (1); }
fgets(comentari,200,fpdades);
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for(i=1;i<=NPT;i++)
{
fscanf(fpdades,"%f",&mz[i]);
jj=1;
for(j=1;j<=diestot;j++)
{
fscanf(fpdades,"%f",&valintensity);
if(opt[j]==1)
{
intensity[jj][i]=valintensity;
// printf("%d %d %f\n",jj,i,intensity[jj][i]);
jj++;
}
}
}
printf("Reading: Primer punt: %f ",mz[1]);
for(j=1;j<=DIES;j++)
{ printf("%f ",intensity[j][1]); }
printf("\n");
printf("Reading: Ultim punt (%d): %f ",NPT, mz[NPT]);
for(j=1;j<=DIES;j++)
{ printf("%f ",intensity[j][NPT]); }
printf("\n");
fclose(fpdades);
/* Lectura de les variables */
punt_xc1=1;
punt_xc2=1;
punt_xc3=1;
punt_xc4=1;
for(i=1;i<=NPT;i++)
{
if(fabs(mz[punt_xc1]-xc1_ini[1])>fabs(mz[i]-xc1_ini[1]))
{ punt_xc1=i; }
if(fabs(mz[punt_xc2]-xc2_ini[1])>fabs(mz[i]-xc2_ini[1]))
{ punt_xc2=i; }
if(fabs(mz[punt_xc3]-xc3_ini[1])>fabs(mz[i]-xc3_ini[1]))
{ punt_xc3=i; }
if(fabs(mz[punt_xc4]-xc4_ini[1])>fabs(mz[i]-xc4_ini[1]))
{ punt_xc4=i; }
}
for(j=1;j<=DIES;j++)
{ yb0_ini[j]=intensity[j][1];
pa1_ini[j]=intensity[j][punt_xc1];
pa2_ini[j]=intensity[j][punt_xc2];
pa3_ini[j]=intensity[j][punt_xc3];
pa4_ini[j]=intensity[j][punt_xc4];
pw1_ini[j]=w1_ini[j]/sqrt(2);
pw2_ini[j]=w2_ini[j]/sqrt(2);
pw3_ini[j]=w3_ini[j]/sqrt(2);
pw4_ini[j]=w4_ini[j]/sqrt(2);
}
printf("Initial Vabs values from esprectrum \n");
printf("*yb0: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",yb0_ini[j]); } printf("\n");
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printf("*pa1: ");
for(j=1;j<=DIES;j++)
{
printf("%10.2f ",pa1_ini[j]);
} printf("\n");
printf("*xc1: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",xc1_ini[j]); } printf("\n");
printf("w1: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",w1_ini[j]); } printf("\n");
printf("*pw1: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",pw1_ini[j]); } printf("\n");
printf("*pa2: ");
for(j=1;j<=DIES;j++)
{
printf("%10.2f ",pa2_ini[j]);
} printf("\n");
printf("*xc2: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",xc2_ini[j]); } printf("\n");
printf("w2: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",w2_ini[j]); } printf("\n");
printf("*pw2: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",pw2_ini[j]); } printf("\n");
printf("*pa3: ");
for(j=1;j<=DIES;j++)
{
printf("%10.2f ",pa3_ini[j]);
} printf("\n");
printf("*xc3: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",xc3_ini[j]); } printf("\n");
printf("w3: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",w3_ini[j]); } printf("\n");
printf("*pw3: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",pw3_ini[j]); } printf("\n");
printf("*pa4: ");
for(j=1;j<=DIES;j++)
{
printf("%10.2f ",pa4_ini[j]);
} printf("\n");
printf("*xc4: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",xc4_ini[j]); } printf("\n");
printf("w4: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",w4_ini[j]); } printf("\n");
printf("*pw4: ");
for(j=1;j<=DIES;j++)
{ printf("%10.2f ",pw4_ini[j]); } printf("\n");
// Inicialitzar vabs del fitting:
for(j=1;j<=DIES;j++)
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{ pa1[j]=pa1_ini[j];
pa2[j]=pa2_ini[j];
pa3[j]=pa3_ini[j];
pa4[j]=pa4_ini[j];
pw1[j]=pw1_ini[j];
pw2[j]=pw2_ini[j];
pw3[j]=pw3_ini[j];
pw4[j]=pw4_ini[j];
xc1[j]=xc1_ini[j];
xc2[j]=xc2_ini[j];
xc3[j]=xc3_ini[j];
xc4[j]=xc4_ini[j]; }
y=vector(1,MP);
p=matrix(1,MP,1,NP);
NoNegs=1 ; /* Keyword: Per no tenir coeficients negatius */
//////////////////
p[1][1]=xc1_ini[1];
p[1][2]=xc2_ini[1];
p[1][3]=xc3_ini[1];
p[1][4]=xc4_ini[1];
p[1][5]=pw1_ini[1];
p[1][6]=pw2_ini[2];
p[1][7]=pw3_ini[3];
p[1][8]=pw4_ini[4];
y[1]=fitexperimentsMult(p[1]);
chiq_min=y[1];
printf("*** RESULTAT y[1]= %f\n",y[1]);
fdelta=1;
p[2][1]=p[1][1]+(ran1(&idum)-0.5)*fdelta;
p[2][2]=p[1][2];
p[2][3]=p[1][3];
p[2][4]=p[1][4];
p[2][5]=p[1][5];
p[2][6]=p[1][6];
p[2][7]=p[1][7];
p[2][8]=p[1][8];
y[2]=fitexperimentsMult(p[2]);
printf("RESULTAT y[2]= %f\n",y[2]);
p[3][1]=p[1][1];
p[3][2]=p[1][2]+(ran1(&idum)-0.5)*fdelta;
p[3][3]=p[1][3];
p[3][4]=p[1][4];
p[3][5]=p[1][5];
p[3][6]=p[1][6];
p[3][7]=p[1][7];
p[3][8]=p[1][8];
y[3]=fitexperimentsMult(p[3]);
printf("RESULTAT y[3]= %f\n",y[3]);
p[4][1]=p[1][1];
p[4][2]=p[1][2];
p[4][3]=p[1][3]+(ran1(&idum)-0.5)*fdelta;
p[4][4]=p[1][4];
p[4][5]=p[1][5];
p[4][6]=p[1][6];
p[4][7]=p[1][7];
p[4][8]=p[1][8];
3.3. MATERIALS AND METHODS 53
y[4]=fitexperimentsMult(p[4]);
printf("RESULTAT y[4]= %f\n",y[4]);
p[5][1]=p[1][1];
p[5][2]=p[1][2];
p[5][3]=p[1][3];
p[5][4]=p[1][4]+(ran1(&idum)-0.5)*fdelta;
p[5][5]=p[1][5];
p[5][6]=p[1][6];
p[5][7]=p[1][7];
p[5][8]=p[1][8];
y[5]=fitexperimentsMult(p[5]);
printf("RESULTAT y[5]= %f\n",y[5]);
p[6][1]=p[1][1];
p[6][2]=p[1][2];
p[6][3]=p[1][3];
p[6][4]=p[1][4];
p[6][5]=p[1][5]+0.1;
p[6][6]=p[1][6];
p[6][7]=p[1][7];
p[6][8]=p[1][8];
y[6]=fitexperimentsMult(p[6]);
printf("RESULTAT y[6]= %f\n",y[6]);
p[7][1]=p[1][1];
p[7][2]=p[1][2];
p[7][3]=p[1][3];
p[7][4]=p[1][4];
p[7][5]=p[1][5];
p[7][6]=p[1][6]+0.1;
p[7][7]=p[1][7];
p[7][8]=p[1][8];
y[7]=fitexperimentsMult(p[7]);
printf("RESULTAT y[7]= %f\n",y[7]);
p[8][1]=p[1][1];
p[8][2]=p[1][2];
p[8][3]=p[1][3];
p[8][4]=p[1][4];
p[8][5]=p[1][5];
p[8][6]=p[1][6];
p[8][7]=p[1][7]+0.1;
p[8][8]=p[1][8];
y[8]=fitexperimentsMult(p[8]);
printf("RESULTAT y[8]= %f\n",y[8]);
p[9][1]=p[1][1];
p[9][2]=p[1][2];
p[9][3]=p[1][3];
p[9][4]=p[1][4];
p[9][5]=p[1][5];
p[9][6]=p[1][6];
p[9][7]=p[1][7];
p[9][8]=p[1][8]+0.1;
y[9]=fitexperimentsMult(p[9]);
printf("RESULTAT y[9]= %f\n",y[9]);
amoeba(p,y,ndim,FTOL,fitexperimentsMult,&nfunc);
printf("\nNumber of function evaluations: %3d\n",nfunc);
printf("Vertices of final 3-d simplex and\n");
printf("function values at the vertices:\n\n");
printf("%3s %10s %12s %12s %14s\n\n",
"i","x[i]","y[i]","z[i]","function");
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for (i=1;i<=MP;i++) {
printf("%3d ",i);
for (j=1;j<=NP;j++) printf("%12.6f ",p[i][j]);
printf("%12.6f\n",y[i]);
}
printf("\n\nRESULTAT FINAL\n\n");
for(NCALC=1;NCALC<=DIES;NCALC++)
{
printf("+++++++++\n");
for(i=1;i<=NPT;i++)
{
ygauss1 = pa1_min[NCALC]*exp(-SQR((mz[i]-xc1_min[NCALC])/pw1_min[NCALC]));
ygauss2 = pa2_min[NCALC]*exp(-SQR((mz[i]-xc2_min[NCALC])/pw2_min[NCALC]));
ygauss3 = pa3_min[NCALC]*exp(-SQR((mz[i]-xc3_min[NCALC])/pw3_min[NCALC]));
ygauss4 = pa4_min[NCALC]*exp(-SQR((mz[i]-xc4_min[NCALC])/pw4_min[NCALC]));
yres[i] = yb0_min[NCALC] + ygauss1+ygauss2+ygauss3+ygauss4;
printf("RES%d: %8.2f %8.2f %8.2f %8.2f %8.2f %8.2f %8.2f \n",
NCALC,mz[i], intensity[NCALC][i], yres[i],ygauss1+yb0_min[NCALC],
ygauss2+yb0_min[NCALC],
ygauss3+yb0_min[NCALC], ygauss4+yb0_min[NCALC]);
}
}
printf("\nValors Finals, Unitats calcul:\n");
printf("## day pa1 xc1 pw1 pa2 xc2 pw2 pa3 xc3 pw3 pa4 xc4 pw4 yb0\n");
for(NCALC=1;NCALC<=DIES;NCALC++)
{
printf("## %d %11.3f %11.3f %11.3f %11.3f
%11.3f %11.3f %11.3f %11.3f %11.3f %11.3f
%11.3f %11.3f %11.3f \n ",NCALC,
pa1_min[NCALC],xc1_min[NCALC], pw1_min[NCALC],
pa2_min[NCALC],xc2_min[NCALC], pw2_min[NCALC],
pa3_min[NCALC],xc3_min[NCALC], pw3_min[NCALC],
pa4_min[NCALC],xc4_min[NCALC], pw4_min[NCALC],
yb0_min[NCALC]);
}
printf("\nValors Finals, Unitats Dades:\n");
printf("## day A1 xc1 w1 A2 xc2 w2 i A3 xc3 w3 A4 xc4 w4 yb0\n");
for(NCALC=1;NCALC<=DIES;NCALC++)
{
printf("## %d %s %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f
%11.3f %11.3f %11.3f %11.3f \n ",NCALC,nom[index[NCALC]],
pa1_min[NCALC]*sqrt(PI)*pw1_min[NCALC],xc1_min[NCALC], pw1_min[NCALC]*sqrt(2),
pa2_min[NCALC]*sqrt(PI)*pw2_min[NCALC],xc2_min[NCALC], pw2_min[NCALC]*sqrt(2),
pa3_min[NCALC]*sqrt(PI)*pw3_min[NCALC],xc3_min[NCALC], pw3_min[NCALC]*sqrt(2),
pa4_min[NCALC]*sqrt(PI)*pw4_min[NCALC],xc4_min[NCALC], pw4_min[NCALC]*sqrt(2),
yb0_min[NCALC]);
}
printf("CHIQTOTAL: %f \n CHI_INDV: \n",chiq_min);
for(NCALC=1;NCALC<=DIES;NCALC++)
{ printf("%d %s %f ",NCALC,nom[index[NCALC]],chiqdies_min[NCALC]); printf("\n");}
printf("En Per 100: \n ");
for(NCALC=1;NCALC<=DIES;NCALC++)
{ printf("%d %s %f ",NCALC,nom[index[NCALC]],100*chiqdies_min[NCALC]/chiq_min);
printf("\n"); }
free_matrix(p,1,MP,1,NP);
free_vector(y,1,MP);
return(0);
}
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/////////////////////////////
float fitexperimentsMult(float xcenters[8+1])
{
//float chi1,chi2,chi3,chi4,chi5,chi6,chi7,chi8,chitotal;
float chitotal;
float chiexp[DIES+1];
int canvi,i;
for(NCALC=1;NCALC<=DIES;NCALC++)
{
//NCALC=1;
canvi=0;
// FIXAR VALORS: 0
// pre-exp xc sig
fix[1]=fit_g1; fix[2]=0; fix[3]=0;
fix[4]=fit_g2; fix[5]=0; fix[6]=0;
fix[7]=fit_g3; fix[8]=0; fix[9]=0;
fix[10]=fit_g4; fix[11]=0; fix[12]=0;
fix[13]=1;
if(pa1[NCALC]<0) { pa1[NCALC]=10000; } /* Canvi de signe, per la seguent iteracio´ */
if(pa2[NCALC]<0) { pa2[NCALC]=10000; } /* Canvi de signe, per la seguent iteracio´ */
if(pa3[NCALC]<0) { pa3[NCALC]=10000; } /* Canvi de signe, per la seguent iteracio´ */
if(pa4[NCALC]<0) { pa4[NCALC]=10000; } /* Canvi de signe, per la seguent iteracio´ */
if(fix[1]==0) { pa1[NCALC]=0; } /* Si no s’ajusta, la gaussiana es fa 0 */
if(fix[4]==0) { pa2[NCALC]=0; } /* Si no s’ajusta, la gaussiana es fa 0 */
if(fix[7]==0) { pa3[NCALC]=0; } /* Si no s’ajusta, la gaussiana es fa 0 */
if(fix[10]==0) { pa4[NCALC]=0; } /* Si no s’ajusta, la gaussiana es fa 0 */
chiexp[NCALC]=fit4gauss(xcenters);
printf("** RESULTAT Pel CAS %d CHI= %f\n",NCALC,chiexp[NCALC]);
printf("** Valors fixats: ");
for(i=1;i<=13;i++)
{ printf("%d ",fix[i]); }
printf("\n");
printf("** %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f
%11.3f %11.3f %11.3f",
pa1[NCALC],xc1[NCALC], pw1[NCALC],
pa2[NCALC],xc2[NCALC],pw2[NCALC],
pa3[NCALC],xc3[NCALC], pw3[NCALC],
pa4[NCALC],xc4[NCALC], pw4[NCALC],yb0[NCALC]);
printf("\n");
if(NoNegs==1)
{
if(pa1[NCALC]<0) { pa1[NCALC]=0; fix[1]=0; canvi=1; }
/* Canvi de signe, per la seguent iteracio´ */
if(pa2[NCALC]<0) { pa2[NCALC]=0; fix[4]=0; canvi=1; }
/* Canvi de signe, per la seguent iteracio´ */
if(pa3[NCALC]<0) { pa3[NCALC]=0; fix[7]=0; canvi=1; }
/* Canvi de signe, per la seguent iteracio´ */
if(pa4[NCALC]<0) { pa4[NCALC]=0; fix[10]=0; canvi=1; }
/* Canvi de signe, per la seguent iteracio´ */
while(canvi==1) {
canvi=0;
chiexp[NCALC]=fit4gauss(xcenters);
if(pa1[NCALC]<0) { pa1[NCALC]=0; fix[1]=0; canvi=1; }
/* Canvi de signe, per la seguent iteracio´ */
if(pa2[NCALC]<0) { pa2[NCALC]=0; fix[4]=0; canvi=1; }
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/* Canvi de signe, per la seguent iteracio´ */
if(pa3[NCALC]<0) { pa3[NCALC]=0; fix[7]=0; canvi=1; }
/* Canvi de signe, per la seguent iteracio´ */
if(pa4[NCALC]<0) { pa4[NCALC]=0; fix[10]=0; canvi=1; }
/* Canvi de signe, per la seguent iteracio´ *
}
printf("** Fixant1: RESULTAT Pel CAS %d CHI= %f\n",NCALC,chiexp[NCALC]);
printf("** Valors fixats: ");
for(i=1;i<=13;i++)
{ printf("%d ",fix[i]); }
printf("\n");
printf("** %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f %11.3f
%11.3f %11.3f %11.3f",
pa1[NCALC],xc1[NCALC], pw1[NCALC],
pa2[NCALC],xc2[NCALC],pw2[NCALC],
pa3[NCALC],xc3[NCALC], pw3[NCALC],
pa4[NCALC],xc4[NCALC], pw4[NCALC],yb0[NCALC]);
printf("\n");
}
}
/**************/
chitotal=0;
for(NCALC=1;NCALC<=DIES;NCALC++)
{ chitotal+=chiexp[NCALC]; }
printf("** CHI2 TOTAL %f\n",chitotal);
if(chitotal<chiq_min)
{
chiq_min=chitotal;
for(i=1;i<=DIES;i++)
{
pa1_min[i]=pa1[i];
pa2_min[i]=pa2[i];
pa3_min[i]=pa3[i];
pa4_min[i]=pa4[i];
pw1_min[i]=pw1[i];
pw2_min[i]=pw2[i];
pw3_min[i]=pw3[i];
pw4_min[i]=pw4[i];
xc1_min[i]=xc1[i];
xc2_min[i]=xc2[i];
xc3_min[i]=xc3[i];
xc4_min[i]=xc4[i];
yb0_min[i]=yb0[i];
}
}
for(NCALC=1;NCALC<=DIES;NCALC++)
{ chiqdies_min[NCALC]=chiexp[NCALC]; }
return(chitotal);
}
////////////////////////////////7
float fit4gauss(float xcenters[8+1])
{
#define NumVabs 13
long idum=(-911);
int i,*ia,itst,j,k,mfit=NumVabs;
float alamda,chisq,ochisq,*x,*y,*sig,**covar,**alpha;
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float *yres1;
float a[NumVabs+1];
float a1[NumVabs+1];
ia=ivector(1,NumVabs);
x=vector(1,NPT);
y=vector(1,NPT);
yres1=vector(1,NPT);
sig=vector(1,NPT);
covar=matrix(1,NumVabs,1,NumVabs);
alpha=matrix(1,NumVabs,1,NumVabs);
for(i=1;i<=NPT;i++)
{
x[i]=mz[i];
y[i]=intensity[NCALC][i];
sig[i]=1.;
}
//Entrada valors:
a[1]=pa1[NCALC];
a[2]=xcenters[1];
a[3]=xcenters[5];
a[4]=pa2[NCALC];
a[5]=xcenters[2];
a[6]=xcenters[6];
a[7]=pa3[NCALC];
a[8]=xcenters[3];
a[9]=xcenters[7];
a[10]=pa4[NCALC];
a[11]=xcenters[4];
a[12]=xcenters[8];
a[13]=yb0[NCALC];
// FIXAR VALORS: 0
ia[1]=fix[1];
ia[2]=fix[2];
ia[3]=fix[3];
ia[4]=fix[4];
ia[5]=fix[5];
ia[6]=fix[6];
ia[7]=fix[7];
ia[8]=fix[8];
ia[9]=fix[9];
ia[10]=fix[10];
ia[11]=fix[11];
ia[12]=fix[12];
ia[13]=fix[13];
printf("Valors: ");
for(j=1;j<=NumVabs;j++) { printf("%10.2f ",a[j]); } printf(" \n");
alamda = -1;
mrqmin(x,y,sig,NPT,a,ia,NumVabs,covar,alpha,&chisq,fgauss3,&alamda);
k=1;
itst=0;
for (;;) {
printf("\n%s %2d %17s %10.4f %10s %9.2e\n","Iteration #",k,
"chi-squared:",chisq,"alamda:",alamda);
printf("%8s %8s %8s %8s %8s %8s ...\n",
"a[1]","a[2]","a[3]","a[4]","a[5]","a[6]");
for (i=1;i<=NumVabs;i++) printf("%11.3f",a[i]);
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printf("\n");
k++;
ochisq=chisq;
mrqmin(x,y,sig,NPT,a,ia,NumVabs,covar,alpha,&chisq,fgauss4,&alamda);
if (chisq > ochisq)
itst=0;
else if (fabs(ochisq-chisq) < 0.01)
itst++;
if (itst < 8) continue;
alamda=0.0;
mrqmin(x,y,sig,NPT,a,ia,NumVabs,covar,alpha,&chisq,fgauss4,&alamda);
printf("\nUncertainties:\n");
for (i=1;i<=NumVabs;i++) printf("%11.3f",sqrt(covar[i][i]));
printf("\n");
break;
}
/* Guardar els resultats a vabs globals */
pa1[NCALC]=a[1];
xc1[NCALC]=a[2];
pw1[NCALC]=a[3];
pa2[NCALC]=a[4];
xc2[NCALC]=a[5];
pw2[NCALC]=a[6];
pa3[NCALC]=a[7];
xc3[NCALC]=a[8];
pw3[NCALC]=a[9];
pa4[NCALC]=a[10];
xc4[NCALC]=a[11];
pw4[NCALC]=a[12];
yb0[NCALC]=a[13];
/* Per Imprimir me´s resultats */
// for(i=1;i<=NPT;i++)
// {
// yres1[i]=0.0;
// for (j=1;j<=MA;j+=3) {
// yres1[i] += a[j]*exp(-SQR((x[i]-a[j+1])/a[j+2]));
// }
// printf("RES: %7.2f %8.2f %8.2f \n",x[i],y[i],yres1[i]);
// }
free_matrix(alpha,1,NumVabs,1,NumVabs);
free_matrix(covar,1,NumVabs,1,NumVabs);
free_vector(sig,1,NPT);
free_vector(y,1,NPT);
free_vector(yres1,1,NPT);
free_ivector(ia,1,NumVabs);
free_vector(x,1,NPT);
return(chisq) ;
}
/////////////////////////////7
float fit3gauss(float xcenters[6+1])
{
#define NumVabs 10
long idum=(-911);
int i,*ia,itst,j,k,mfit=NumVabs;
float alamda,chisq,ochisq,*x,*y,*sig,**covar,**alpha;
float *yres1;
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float a[NumVabs+1];
float a1[NumVabs+1];
ia=ivector(1,NumVabs);
x=vector(1,NPT);
y=vector(1,NPT);
yres1=vector(1,NPT);
sig=vector(1,NPT);
covar=matrix(1,NumVabs,1,NumVabs);
alpha=matrix(1,NumVabs,1,NumVabs);
for(i=1;i<=NPT;i++)
{
x[i]=mz[i];
y[i]=intensity[NCALC][i];
sig[i]=1.;
}
//Entrada valors:
a[1]=pa1[NCALC];
a[2]=xcenters[1];
a[3]=xcenters[4];
a[4]=pa2[NCALC];
a[5]=xcenters[2];
a[6]=xcenters[5];
a[7]=pa3[NCALC];
a[8]=xcenters[3];
a[9]=xcenters[6];
a[10]=yb0[NCALC];
// FIXAR VALORS: 0
ia[1]=fix[1];
ia[2]=fix[2];
ia[3]=fix[3];
ia[4]=fix[4];
ia[5]=fix[5];
ia[6]=fix[6];
ia[7]=fix[7];
ia[8]=fix[8];
ia[9]=fix[9];
ia[10]=fix[10];
printf("Valors: ");
for(j=1;j<=NumVabs;j++) { printf("%10.2f ",a[j]); } printf(" \n");
alamda = -1;
mrqmin(x,y,sig,NPT,a,ia,NumVabs,covar,alpha,&chisq,fgauss3,&alamda);
k=1;
itst=0;
for (;;) {
printf("\n%s %2d %17s %10.4f %10s %9.2e\n","Iteration #",k,
"chi-squared:",chisq,"alamda:",alamda);
printf("%8s %8s %8s %8s %8s %8s ...\n",
"a[1]","a[2]","a[3]","a[4]","a[5]","a[6]");
for (i=1;i<=NumVabs;i++) printf("%11.3f",a[i]);
printf("\n");
k++;
ochisq=chisq;
mrqmin(x,y,sig,NPT,a,ia,NumVabs,covar,alpha,&chisq,fgauss3,&alamda);
if (chisq > ochisq)
itst=0;
else if (fabs(ochisq-chisq) < 0.1)
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itst++;
if (itst < 4) continue;
alamda=0.0;
mrqmin(x,y,sig,NPT,a,ia,NumVabs,covar,alpha,&chisq,fgauss3,&alamda);
printf("\nUncertainties:\n");
for (i=1;i<=NumVabs;i++) printf("%11.3f",sqrt(covar[i][i]));
printf("\n");
break;
}
/* Guardar els resultats a vabs globals */
pa1[NCALC]=a[1];
xc1[NCALC]=a[2];
pw1[NCALC]=a[3];
pa2[NCALC]=a[4];
xc2[NCALC]=a[5];
pw2[NCALC]=a[6];
pa3[NCALC]=a[7];
xc3[NCALC]=a[8];
pw3[NCALC]=a[9];
yb0[NCALC]=a[10];
/* Per Imprimir mes resultats */
// for(i=1;i<=NPT;i++)
// {
// yres1[i]=0.0;
// for (j=1;j<=MA;j+=3) {
// yres1[i] += a[j]*exp(-SQR((x[i]-a[j+1])/a[j+2]));
// }
// printf("RES: %7.2f %8.2f %8.2f \n",x[i],y[i],yres1[i]);
// }
free_matrix(alpha,1,NumVabs,1,NumVabs);
free_matrix(covar,1,NumVabs,1,NumVabs);
free_vector(sig,1,NPT);
free_vector(y,1,NPT);
free_vector(yres1,1,NPT);
free_ivector(ia,1,NumVabs);
free_vector(x,1,NPT);
return(chisq) ;
}
/////////////////////////////7
#undef NRANSI
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Evaluation of small molecules
4.1 Results
4.1.1 Selection of molecules described to have an eﬀect on Aβ
aggregation
There are many reports with in vitro studies in which small molecules are shown to enhance
or inhibit Aβ aggregation (for a review see [108, 109]). However, most of them fail to give
detailed information on the mechanism of action of these small molecules an thus it is not
known the type of Aβ aggregate with which they interact and/or stabilize.
We chose to work with Aβ42 since this variant is most strongly linked to AD etiology
than other Aβ forms. We tested the eﬀect of a small library of diﬀerent compounds on
Aβ42 aggregation. The library comprised twenty small molecules (Figure 4.1) with diﬀerent
chemical characteristics (functional groups, ﬂexibility, salts) fulﬁlling at least one of the
following requirements:
• Targeting Aβ aggregation and amyloidogenesis being or having been in clinical tri-
als against AD. These include ammonium tetrathio-molybdate [90], clioquinol [89],
epigallocatechin gallate [87, 88], scyllo-inositol [85] and its isomer myo-inositol, taren-
ﬂurbil [110] and tramiprosate [81].
• Inhibiting Aβ ﬁbril formation by stabilizing Aβ oligomers in vitro. These comprise
apigenin [77], chicago sky blue 6B [77], diallyltartardiamide [77], direct red 80 [77],
orange G [77], riluzole [83] and tetracycline [82].
• Delaying Aβ ﬁbril formation in vitro. These include 2,2’-dihydroxybenzophenone [77],
entacapone [79], inrD [93] and salvianolic acid B [80].
• Inhibiting Aβ oligomer formation but not ﬁbrillization in vitro. These comprise 2,2’-
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dihydroxybenzophenone [77], juglone [77] and methylene blue [77].
4.1.2 First screening of molecules interfering with Aβ aggregation
using the ﬁlter-retardation assay (FRA)
To carry out a ﬁrst screening on the eﬀect of the 20 molecules comprising our library on
Aβ42 aggregation, we used the FRA (Figure 4.2). This assay is a fast, quantitative method
to screen for the eﬀect of compounds against the formation of large, SDS-stable Aβ ag-
gregates. [111, 112]. After diﬀerent aggregation times (Δtagg), aliquots of the aggregating
solution were removed and stored at -20◦C. When all the samples were collected, they were
diluted, SDS-treated to a ﬁnal SDS concentration of 2% and heated at 95◦C for 5 min-
utes, to disrupt all non-resistant SDS Aβ aggregates. Those SDS-treated samples were
ﬁltered through a cellulose acetate membrane. By using the FRA, high molecular weight,
SDS-resistant aggregates are retained in the membrane, while monomeric peptide and small
soluble Aβ oligomers pass through the membrane. The amount of SDS-resitant aggregates
was quantiﬁed by immunodetection using the monoclonal antibody 6E10, which speciﬁcally
recognizes the N-terminus end of the Aβ peptide.
We followed the aggregation of Aβ42 alone and in the presence of the molecules comprising
our library during 12 days. These experiments were carried out by Ricard Illa, an under-
graduate student that spent three months working with us. Aβ42 aggregation in the absence
of molecules was monitored using both the ThT binding assay and the FRA. Interestingly,
we obtained a correspondence between the ﬂuorescence signal of the ThT binding assay and
the immunosignal of the FRA (Figure 4.3). Thus, the end of the lag phase assessed by ThT
was consistent with the appearance of SDS-resistant aggregates, suggesting that Aβ42 ﬁbrils
were the only SDS-resistant aggregates. The ThT binding assay cannot be used to study
Aβ42 aggregation in the presence of small molecules, as the small molecule might interfere
with the ﬂuorescence excitation or emission needed for ThT and/or the small molecule might
inhibit the formation of the complex between ThT and a ﬁbril [113]. Most of the molecules
tested accelerated the formation of SDS-resistant aggregates. The degree in which they accel-
erated the process varied from molecule to molecule. The molecules exhibiting this activity,
ordered from higher to lower enhancing ability were: orange G, diallyltartardiamide, am-
monium tetrathiomolybdate, chicago sky blue 6B, entacapone, myo-inositol, scyllo-inositol,
juglone, clioquinol, tarenﬂurbil, tramiprosate, apigenin, riluzole and salvianolic acid B. On
the other hand, some molecules like methylene blue, 2,2’-dihydroxybenzophenone and tetra-
cycline did not show a clear eﬀect on Aβ42 aggregation, exhibiting a pattern comparable
to Aβ42 alone. Finally, epigallocatechin gallate slowed down the formation of SDS-resistant
aggregates and the peptide inrD showed the most remarkable inhibitory eﬀect on Aβ42
aggregation.
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Figure 4.1: The chemical structure of the twenty molecules composing our library and as-
sessed in this study.
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Figure 4.2: Schematic description of the FRA. Three hypothetical samples are depicted: a
control of Aβ42, Aβ42 in the presence of small molecule A (in blue) which has no eﬀect
on Aβ42 aggregation, and Aβ42 incubated with small molecule B (in red), which enhances
Aβ42 ﬁbrillization.
4.1.3 Evaluation of the eﬀect of small molecules and inrD on Aβ42
using the PL-HDX-ESI-MS experiment
Using the PL-HDX-ESI-MS experiment in Chapter 3, we have detected, characterized and
quantiﬁed three diﬀerent species during Aβ42 aggregation. This result provided us with an
opportunity to study the eﬀect of compounds on the species detected and thus learn about
their mechanism of action.
Based on the results obtained with the FRA, we selected a small, representative number of
compounds for further studies using the PL-HDX-ESI-MS experiment. We did not choose
molecules exhibiting solubility problems as well as salts. We chose diallyltartardiamide
(DATD) and entacapone (Ent) as representative compounds of those enhancing Aβ42 ag-
gregation, 2,2’-dihydroxy-benzophenone (DHB) as small molecule not having an eﬀect on
Aβ42 aggregation and epigallocatechin gallate (EGCG) and inrD as inhibitors of Aβ42 ag-
gregation.
We performed a new round of aggregation experiments with Aβ42, Aβ42 + Ent, Aβ42
+ DATD, Aβ42 + DHB, Aβ42 + inrD and Aβ42 + EGCG, applying the PL-HDX-ESI-
MS experiment (Figure 4.5). The MS spectra were adjusted to three species in all cases
except for Aβ42 + inrD where two species were necessary, according to the error analysis
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Figure 4.3: Monitoring of Aβ42 aggregation in the presence of the 20 compounds. A) Aβ42
aggregation in the absence of any compound monitored by the ThT binding assay. B) Aβ42
aggregation monitored in the absence (top row) and in the presence (second to twentieth row)
of the 20 compounds comprising our library by the FRA. Most of the compounds enhanced
Aβ aggregation, while others did not have a clear eﬀect on the process. Epigallocatechin
gallate and the peptide inrD exhibited a remarkable inhibitory eﬀect.
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Figure 4.4: The PL-HDX experiment to study Aβ aggregation in the presence of a small
molecule: A) Schematic representation of the experiment. B) Hypothetical scenario for a
given aggregation time Δtagg in the absence of the small molecule (top) and in the presence
of a small molecule enhancing Aβ ﬁbrillization (bottom).
mentioned in the previous chapter (Table 4.1, Materials and Methods). For Aβ42, three
diﬀerent species were detected. The number of exposed amides for each of the detected
species were not signiﬁcantly diﬀerent from the ones obtained for Aβ42 in the previous
chapter (they correspond to a diﬀerent experiment) (Figure 4.5). Also in agreement with
the results obtained for Aβ42 in the previous chapter, PFAβ42 and EAAβ42 were the most
heterogeneous species formed during aggregation (Figure 4.7).
Ent and DATD accelerate Aβ42 aggregation
We studied Aβ42 aggregation in the presence of DATD and Ent by means of the PL-HDX-
ESI-MS experiment. In both cases, error analysis (Table 4.1, Materials and Methods) in-
volved the adjustment of the spectra to three species (Figure 4.5).
Since no signiﬁcant diﬀerences were observed in the number of exposed amides for the species
detected in the absence or in the presence of Ent and DATD (Figure 4.6), we named them as
EA, PF and F adding a subscript to indicate the chemical compound under study. For Aβ42
+ Ent, EAAβ42+Ent displays 30± 1 while for Aβ42 + DATD the value for EAAβ42+DATD is 29.8
± 0.9. PFAβ42+Ent is 18 ± 1, while PFAβ42+DATD is 20 ± 2. FAβ42+Ent is 12.9 ± 0.8, whereas
FAβ42+DATD is 13.7 ± 0.7. Note that these values did not diﬀer signiﬁcantly from those for
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Figure 4.5: PL-HDX-ESI-MS results for Aβ42 in the absence and in the presence of small
molecules and a peptide. All the spectra were adjusted to three gaussian curves except for
Aβ42 + inrD, in which two gaussians were used. A) Aβ42 in the absence of inhibitors. B)
Aβ42 in the presence of entacapone (Ent). C) Aβ42 aggregating with diallyltartardiamide
(DATD). D) Aβ42 in the presence of 2,2’-dihydroxybenzophenone (DHB). E) Aβ42 aggre-
gation in the presence of the peptide inrD.
Aβ42 in the absence of small molecule. Similarly to Aβ42 aggregating alone, the presence of
Entacapone or Diallyltartardiamide did not inﬂuence signiﬁcantly the heterogeneity of the
species formed during the process of aggregation (Figure 4.7).
PL-HDX-ESI-MS experiments allowed us to establish that Ent and DATD aﬀected the rela-
tive population of species as a function of time (Figure 4.8). These two small molecules led
to a faster decrease of the EAAβ42+Ent and EAAβ42+DATD populations with PFAβ42+Ent and
PFAβ42+DATD being maximal after two days of aggregation and ﬁbrils appearing 2-3 days
earlier than in the absence of small molecules. These two small molecules accelerated the
kinetics of Aβ42 ﬁbrillization.
68 CHAPTER 4. EVALUATION OF SMALL MOLECULES
Figure 4.6: Number of exposed amides for each of the
species detected during Aβ42 aggregation in the ab-
sence and in the presence of the compounds assayed.
Number of exposed amides corresponding to the (A)
EAAβ42 species, (B) the PFAβ42 species and the (C)
FAβ42 species in the absence and in the presence of the
compounds assayed.
DHB enhances the formation of high-order aggregates of Aβ42
When we applied the PL-HDX-ESI-MS experiment to Aβ42 aggregating with DHB we found
that this small molecule involved the formation of three diﬀerent species (Figure 4.5; Table
4.1, Materials and Methods). Although the number of exposed amides for each detected
species was slightly higher than for EAAβ42, PFAβ42 adn FAβ42, the increase was not signif-
icant so we named them as: EAAβ42+DHB (32 ± 1 exposed amides), PFAβ42+DHB (21 ± 2
exposed amides) and FAβ42+DHB (13.7 ± 0.8 exposed amides) (Figure 4.6). Regarding the
heterogeneous nature of the species detected, EAAβ42+DHB was slightly less heterogeneous
than that observed for other molecules (Figure 4.7).
The presence of DHB enhanced the formation of PFAβ42+DHB species, being maximal after
1 day of aggregation. EAAβ42+DHB population decreased remarkably fast and FAβ42+DHB
species were present from day 3 onwards, although their relative abundance was much lower
than that detected in its absence (Figure 4.8). Thus PL-HDX-ESI-MS experiments revealed
that the mechanism of action of DHB was stabilizing the formation of PFAβ42+DHB but not
ﬁbrils.
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Figure 4.7: Peak widths for each of the species detected
during Aβ42 aggregation in the absence and in the pres-
ence of the compounds assayed. Peak widths values cor-
responding to the (A) EAAβ42 species, (B) the PFAβ42
species and the (C) FAβ42 species in the absence and in
the presence of the compounds assayed.
inrD inhibits Aβ42 aggregation by oligomer stabilization
Next, we applied the PL-HDX-ESI-MS experiment to study the eﬀect of the peptide inrD in
Aβ42 aggregation. In this case, we found that the spectra were ﬁt to just two gaussian curves
(Figure 4.5; Table 4.1, Materials and Methods). The number of exposed amides of the two
species detected were similar to EAAβ42 and PFAβ42, thus we named them EAAβ42+inrD (31
± 1) and PFAβ42+inrD (20 ± 2) (Figure 4.6): It is signiﬁcant to notice that no F population
was present. It is also signiﬁcant to notice that PFAβ42+inrD population is as heterogeneous
as EAAβ42+inrD (Figure 4.7). During the timescale of our experiment, inrD inhibited Aβ42
ﬁbrillization by stabilizing an oligomer, PFAβ42+inrD (Figure 4.8).
EGCG chemically modiﬁes Aβ42
When we applied the PL-HDX-ESI-MS experiment to study Aβ42 aggregation in the pres-
ence of EGCG, we obtained complex MS spectra: we observed m/z values higher than what
we would expect for fully deuterated Aβ42 (Figure 4.9A). Besides, the signal to noise ratio
for the spectra was poorer when increasing Δtagg. To shed light onto this unexpected re-
sult, we performed the PL-HDX-ESI-MS experiment on the same samples and aggregation
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Figure 4.8: Eﬀect of small molecules and a peptide on
Aβ42 aggregation. A) ThT binding assay monitoring
Aβ42 aggregation in the absence of compounds. Popu-
lation of the diﬀerent species detected during (B) Aβ42
aggregation and in the presence of (C) DATD, (D) Ent,
(E) DHB and (F) inrD.
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time points but without exchanging the protonated buﬀer tot deuterated one (Figure 4.9B).
Under these conditions, all the spectra should show a single peak corresponding to the m/z
value of fully protonated Aβ42. However, we observed a second peak corresponding to a
mass 16 units higher than fully protonated Aβ42. Moreover, the intensity of this second
peak increased at longer aggregation times. Based on the increment in mass, we assigned
this second peak to an oxidized form of Aβ42 (the atomic weight of oxygen is approximately
16 uma), and we suspected that the sulﬁde group of methionine 35 had undergone oxidation.
Figure 4.9: EGCG chemically modiﬁes Aβ42. A) PL-HDX-ESI-MS scheme and ESI-MS
spectra for Aβ42 aggregation in the presence of EGCG. B) Modiﬁed PL-HDX-ESI-MS
scheme showing that no buﬀer exchange to D2O is performed and corresponding ESI-MS
spectra. Red and blue bars indicate, respectively, expected m/z values for fully deuterated
and fully protonated Aβ42.
We were able to conﬁrm by NMR studies that in the presence of EGCG, Aβ42 was oxidized
in its sulﬁde group of methionine 35. Since the sulﬁde and the sulfoxide group involve
diﬀerent chemical environments, the chemical shift of the methyl protons adjacent to these
two chemical groups are diﬀerent and can be quantiﬁed by NMR. Using 13C(CH3)Met35-
Aβ42, that is, Aβ42 where the methyl group in methionine 35 is labeled with 13C, we
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recorded a series of 2D 1H−13C Heteronuclear Multiple Quantum Correlation (HMQC) NMR
spectra at the initial stage of aggregation and after 1.5, 3 and 4 days of aggregation (Figure
4.10). Projection of the 2D 1H−13C HMQC spectra on the 1H dimension showed two peaks,
corresponding to the methyl protons of non-oxidized (at 2 ppm) and oxidized methionine
(at 2.4 ppm). We observed a sharp decrease in the intensity of the non-oxidized methyl of
methionine 35 as a function of the aggregation time. This result can be explained by the fact
that large aggregates cannot be detected by solution NMR. Since the signal corresponding
to the oxidized methyl of methionine 35 showed a similar intensity as aggregation proceeded,
we showed further evidence that EGCG covalently modiﬁed by oxidation the Aβ42 peptide.
Hence, in the presence of EGCG, Aβ42 suﬀered a chemical modiﬁcation, the oxidation of its
sulﬁde group in methionine 35.
Figure 4.10: Superposition of the 1H projection of the bidimensional 1H−13C HMQC NMR
spectra obtained during Aβ42 aggregation in the presence of EGCG. The chemical shift of
the methyl group of methionine 35 (in orange) appears at 2 ppm and 2.4 ppm, respectively,
in the non-oxidized and oxidized form of Aβ42. Aggregation was monitored at 0 days (blue),
1.5 days (red), 3 days (green) and 4 days (violet).
4.2 Discussion
In Chapter 3, we showed that PL-HDX-ESI-MS experiments overcome the heterogeneity of
the aggregation process, enabling to detect, characterize and quantify the diﬀerent species
populating during Aβ42 aggregation. We found this methodology to yield very useful and
valuable information regarding the mechanism of action ﬁve molecules described to modulate
Aβ42 aggregation.
The FRA proved to be a good way to screen a library of compounds. Although the infor-
mation obtained was limited, it enabled to have a ﬁrst idea of the behavior of several small
molecules and a peptide towards Aβ42 aggregation and was a useful tool to select candidates
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for a further study. Since the immunoblot intensity clearly correlated with the ThT binding
assay, our results indicated that the FRA quantiﬁed the amount of Aβ42 ﬁbrils (Figure 4.3).
Both Ent and DATD were shown to accelerate Aβ42 aggregation (Figure 4.5 and 4.8). After
applying the PL-HDX-ESI-MS experiment, Ent and DATD were shown to enhance Aβ42
ﬁbrillization: the F population increased faster than in the case when Aβ42 aggregated
without any small molecule, and PFAβ42+Ent and PFAβ42+DATD were also formed faster. This
behavior might be of pharmaceutical relevance. In fact, enhancing ﬁbrillization has also
been posed as a possibility to elude soluble oligomer toxicity. In fact, the group of Erich
Wanker showed that by enhancing the ﬁbrillization of Aβ42, the small molecule O4 was able
to reduce Aβ42 toxicity in vitro [112].
The behavior of Ent and DATD, though, was diﬀerent in our hands from what is reported in
the literature. In an article from the Lashuel group [79], Ent, a catechol O-methyltransferase
inhibitor, currently marketed as a symptomatic treatment against Parkinson’s disease, is
shown to protect PC12 cells against amyloid-induced toxicity by inhibiting Aβ42 aggregation.
The methodology to assess the eﬀect of Aβ42 aggregation in the presence of Ent was the
ThT binding assay and Electron Microscopy. As mentioned, monitoring the ThT binding of
an amyloid in the presence of a small molecule is ill-advised, since there are several problems
associated: the small molecule might interfere with the ﬂuorescence excitation or emission of
ThT and/or the small molecule might inhibit the formation of the complex between ThT and
the Aβ ﬁbril [113]. Moreover, not ﬁnding a large amount of ﬁbrils in a electron microscopy
grid cannot rule out the possibility of having in fact amyloid ﬁbrils in solution that are not as
easily deposited for instance as a consequence of the diﬀerent physicochemical environment
the small molecule might confer.
For DATD, the Glabe group reported that it stabilized oligomers and did not form ﬁbrils [77].
However, the evidence came only by positive immunoreactivity of the aggregates formed by
DATD and Aβ42 against A11 antibody, a conformation speciﬁc antibody detecting only
oligomers [75]. Moreover, no experimental data is shown in the case of DATD in the whole
paper, making diﬃcult to assess why DATD was classiﬁed as having that eﬀect and not
another. In our hands, we found DATD enhanced Aβ42 ﬁbrillization. Since EAAβ42+DATD
and PFAβ42+DATD coexist with FAβ42+DATD, some of them might be positive against A11,
which might explain the result obtained by Glabe and co-workers.
The FRA showed that DHB had a negligible eﬀect on Aβ42, since the pattern was very
similar for Aβ42 + DHB and Aβ42. With the PL experiment we showed that DHB inﬂu-
enced signiﬁcantly Aβ42 aggregation by enhancing the formation of the PFAβ42 species, an
aggregate that was not large enough or stable enough to be detected by the FRA (Figure
4.3).
DHB was shown to inhibit both oligomerization and ﬁbrillization in a report by the Glabe
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group [77]. As stated in the case of DATD, these results were obtained mainly through
the use of A11. We found that DHB slightly inhibited the formation of ﬁbrils (Figure 4.8).
However, we did not found DHB inhibiting the formation of oligomers, as it enhanced the
formation of the oligomer PFAβ42, in apparent contradiction with the activity reported. A
possible explanation might be that PFAβ42, the oligomer stabilized by DHB, is not A11-
positive.
The inrD peptide was developed in our laboratory and shown to inhibit Aβ42 ﬁbrillization by
retarding ﬁbril formation [93]. It also showed a protective eﬀect on SHSY5Y cells. Using PL-
HDX-ESI-MS experiment we found that inrD prevented the formation of the F population
and it stabilized the oligomer PFAβ42, thus inhibiting Aβ42 aggregation. This information
complements the previous work in our laboratory and it sheds light onto the mechanism
of action of this peptide. In the previous work [93], by using photo-induced cross-linking
of unmodiﬁed proteins (PICUP) [114], it was showed that inrD was able to stabilize early-
formed oligomers. In our present work we show inrD stabilizing EAAβ42 and PFAβ42 in a
time-dependent manner. The peptide inrD, whose design is inspired on the Aβ42 sequence,
might be an Aβ42 inhibitor susceptible to further studies in the quest for antiamyloidogenic
therapeutic agents.
EGCG was reported to form oﬀ-pathway, non-toxic Aβ42 aggregates [87]. Further studies
showed that EGCG was able to remodel (disrupt) amyloid ﬁbrils [88] and the reported non-
toxic aggregates had a structure amenable to study [115]. Concomitant with our work with
this small molecule and Aβ42, a recent study contributed to understanding the mechanism
by which EGCG remodeled amyloid ﬁbrils [116]. In this study, the oxidized form of EGCG
is shown to covalently interact with Aβ42 through imine bond formation between amino
residues and carbonyl groups in oxidized EGCG. In fact, this compound is easily oxidized
in the presence of atmospheric oxygen [117].
Taking together our MS and NMR results for Aβ42 + EGCG, we have been able to assess
that EGCG is able to covalently modify Aβ42. We have determined that the sulﬁde group
in methionine 35 is oxidized to a sulfone group (Figures 4.9 and 4.10), probably via a
radical-type reaction in which atmospheric oxygen oxidizes EGCG which oxidizes Aβ42
at its most oxidation-prone place, the sulﬁde in methionie 35. Moreover, we also found
diﬃculties in ionizing the sample for MS study as the aggregation proceeded. Since our
DMSO-based solution has the ability to break even the ﬁbrillar aggregates, we suspect that
Aβ42 aggregates are chemically cross-linked when aggregating.
Moreover, several reports have claimed the important role of methionine 35 in Aβ aggregation
[118, 119, 120]. With our studies we establish a new link between chemical modiﬁcations of
Aβ and small molecule inhibition with an overall impact on Aβ aggregation.
To summarize, the PL-HDX-ESI-MS experiment has been shown to be a highly valuable
technique to detect, characterize and quantify the species formed in Aβ42 aggregation in the
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presence of pharmaceutically and biologically relevant molecules. Moreover, this experiment
have been shown to enable the distinction between the eﬀects that small molecules have on
Aβ aggregation and a tool to give insights into the mechanism of action of these compounds.
4.3 Materials and Methods
The ThT binding assay, the PL-HDX-ESI-MS experiment and its analysis were carried out
as described in Materials and Methods in Chapter 3.
4.3.1 Preparation of Aβ42 in its lowest aggregation state
Aβ42 was prepared using the same protocol and conditions described in Materials and Meth-
ods of Chapter 3: Aβ42 in the aggregating solution was obtained after a SEC and the
concentration was quantiﬁed by HPLC. DMSO was added to the aggregating solution at a
0.5% concentration in order to match the DMSO concentration in Aβ42 aggregating in the
presence of our library compounds.
4.3.2 Small molecule and peptide stocks
2,2’-dihydroxybenzophenone, apigenin, diallyltartardiamide, clioquinol, direct red 80, epigal-
locatechin gallate, juglone, salvianolic acid B, tarenﬂurbil, tetracycline, entacapone, riluzole
and methylene blue were dissolved in DMSO to a ﬁnal concentration of 60 mM. Chicago
sky blue 6B, myo-inositol, orange G, scyllo-inositol and tramiprosate were dissolved in the
same aqueous buﬀer as Aβ42 peptide (50 mM ammonium acetate, 1 mM Tris · HCl, 0.01%
sodium azide, pH 7.4) to a ﬁnal concentration of 60 mM. Ammonium tetrathiomolybdate
was dissolved in DMSO to a ﬁnal concentration of 30 mM and the peptide inrD was dissolved
in DMSO to a ﬁnal concentration of 10 mM.
4.3.3 Aggregation of Aβ42 in the presence of small molecules and
peptide inrD
A volume of small molecule stock was added to a freshly prepared Aβ42 solution so that
all small molecules were at a 10:1 ratio SM:Aβ42 (300 μM small molecule concentration).
Only in the case of the peptide inrD the ratio was kept at 2:1 inrD:Aβ42 (60 μM concen-
tration of inrD). The ﬁnal DMSO concentration in all the aggregating solutions was 0.5%.
Apigenin, clioquinol and juglone weren’t soluble enough in those conditions and precipitated
immediately when they were diluted from the DMSO stock.
76 CHAPTER 4. EVALUATION OF SMALL MOLECULES
4.3.4 FRA
25 μL triplicate aliquots were collected and frozen at diﬀerent times of the aggregation pro-
cess. After collecting aliquots for 12 days, samples were unfrozen and SDS-treated as follows:
225 μL of a 2,22% SDS solution were added to the 25 μL aliquots to obtain a 1/10 dilu-
tion and a ﬁnal SDS concentration of 2%. Then, samples where heated at 95◦C for 5 min.
SDS-treated samples were analyzed using the FRA, using the Bio-Dot SF Microﬁltration
Apparatus (Bio-Rad, CA, US). Samples were ﬁltrated through a cellulose acetate membrane
with a pore size of 0,2 μm (Schleicher and Schuell, Germany). With this method, high molec-
ular weight aggregates are retained in the membrane, while monomeric peptide and small
soluble oligomers are passed through the membrane. The membrane was immunodetected
using the monoclonal antibody 6E10 (Invitrogen, CA, US), which speciﬁcally recognizes the
N-terminus end of the Aβ peptide.
4.3.5 Multigaussian ﬁtting of PL-HDX ESI-MS experiments
The MS spectra for Aβ42 alone and Aβ42 + small molecules/inrD were adjusted to gaussian
curves. According to the error analysis, three species were detected in all cases except for
Aβ42 + inrD, in which two gaussians were enough to ﬁt the adjustment. The error analysis
is depicted in Table 4.1.
4.3.6 NMR spectroscopy
NMR measurements were performed on a Bruker 600 US spectrometer (Bruker, Germany)
equipped with four radiofrequency channels and a cryoprobe. 1H−13C HMQC experiments
were measured at a 1H resonance frequency of 600 MHz. 13C(CH3)Met35-Aβ42 was synthe-
sized by James Elliott at Yale University (New Haven, CT, USA) and prepared as described
in the “Preparation of Aβ42 in its lowest aggregation state” section. EGCG dissolved in
DMSO−d6 was added to a freshly prepared Aβ42 sample at a ﬁnal 300 μM concentration
(10:1 EGCG:Aβ42 ratio). DMSO−d6 was used to reference spectra.
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Aβ42
# gaussian error relative error
1 9,52E+10
2 1,42E+10 85,1
3 8,15E+09 42,4
4 6,98E+09 14,3
Aβ42 + Ent
# gaussian error relative error
1 3,18E+10
2 9,41E+09 70,4
3 4,72E+09 49,8
4 4,01E+09 15,1
Aβ42 + DATD
# gaussian error relative error
1 5,12E+10
2 8,30E+09 83,8
3 4,73E+09 43,0
4 4,35E+09 8,0
Aβ42 + DHB
# gaussian error relative error
1 8,47E+09
2 3,83E+09 54,8
3 1,99E+09 48,1
4 1,76E+09 11,5
Aβ42 + inrD
# gaussian error relative error
1 6,85E+09
2 2,34E+09 65,8
3 2,10E+09 10,5
4 1,98E+09 5,7
Table 4.1: Error analysis for Aβ42 in the presence or absence of diﬀerent small molecules
and inrD.
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Conclusions
The conclusions of the present thesis are the following:
1. Using Pulse-labeling Hydrogen/Deuterium Exchange (PL-HDX) experiments, we have
been able to detect, quantify and characterize diﬀerent aggregates formed during Aβ
aggregation.
2. The fact that the aggregates detected showed distinct degree of protection against
HDX indicates that during Aβ aggregation structural rearrangements take place.
3. E22Δ-Aβ42 immediately forms ﬁbrils upon dissolution, and Aβ42 aggregates faster
than Aβ40.
4. By carrying parallel PL-HDX and neurotoxicity experiments, protoﬁbrillar species,
deﬁned as short and curvilinear protoﬁlaments observed by TEM together with the
most abundant species detected by MS at intermediate aggregation stages, have been
established as the most toxic aggregate to primary neural cultures.
5. The lyophilization step in PL-HDX experiments must be carried out under controlled
conditions.
6. The FRA has proven an eﬃcient method to perform a ﬁrst screening of molecules
modulating Aβ aggregation.
7. Using the PL-HDX experiment we have been able to characterize the mechanism by
which diﬀerent molecules interfere with Aβ aggregation:
Entacapone and Diallyltartardiamide enhance Aβ42 ﬁbrillization by accelerating
the kinetics of ﬁbril formation.
2,2’-dihydroxybenzophenone inhibits Aβ42 aggregation by enhancing the formation
of a deﬁned oligomeric species, PFAβ42+DHB.
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The peptide inrD completely inhibits ﬁbrillization in the timescale studied by sta-
bilizing the eariler aggregates EAAβ42+inrDand the protoﬁbrillar species PFAβ42+inrD.
Epigallocatechin gallate chemically modiﬁes Aβ42 aggregates.
6
Resum
6.1 Introduccio´
La malalatia d’Alzheimer (MA) e´s una malalatia neurodegenerativa, la forma me´s comu´
de deme`ncia i implica una pe`rdua gradual de capacitats cognitives, com la memo`ria. El
principal factor de risc e´s l’edat, i la incide`ncia de la MA es duplica cada 5 anys a partir dels
65. La MA pren el seu nom del Dr. Alois Alzheimer, el psiquiatra alemany que va identiﬁcar
el primer cas l’any 1901. La malaltia es caracteritza pels segu¨ents signes: mort neuronal, i
dipo`sit de plaques amiloides i de cabdells neuroﬁbril·lars.
Als anys 80 es va descobrir que els cabdells neuroﬁbril·lars estaven formats principalment
d’agregats de la prote¨ına tau en forma hiperfosforilada, mentres que la prote¨ına beta-amiloide
(βA) era el component principal de les plaques amiloides. Malgrat les dues prote¨ınes
so´n necessa`ries perque` tingui lloc la pe`rdua neuronal en la MA, l’agent causatiu principal
s’atribueix a la prote¨ına βA.
La prote¨ına βA es produeix pel processament de la prote¨ına precursora amiloide (PPA).
La PPA e´s una prote¨ına transmembrana i per a formar βA, dues secretases actuen en ella:
la β- i la γ-secretasa. Com que la γ-secretasa no actua en un lloc espec´ıﬁc, la prote¨ına
βA es forma en diferents longituds, des de 38 a 43 aminoa`cids. La βA de 40 aminoa`cids
(βA40) e´s la forma me´s abundant, mentres que la formada per 42 aminoa`cids (βA42) e´s
la forma me´s implicada en els de`ﬁcits cognitius associats a la MA. La prote¨ına βA agrega
amb s´ı mateixa, formant espe`cies oligome`riques de baix pes molecular, que evolucionen en
protoﬁbril·les i posteriorment aquestes reverteixen en la formacio´ de ﬁbril·les amiloides, els
components principals de les plaques.
En un primer moment, la comunitat cient´ıﬁca assigna` les ﬁbril·les amiloides com l’entitat
responsable de la neurotoxicitat en la MA. Tanmateix, diversos estudis demostraren la manca
de correlacio´ entre quantitat de plaques amiloides i severitat de la MA, pero` la bona correlacio´
entre severitat de la MA i la quantitat de βA soluble. Per aquesta rao´, la hipo`tesi actual
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treballa amb l’assumpcio´ que les espe`cies interme`dies en l’agregacio´ de βA (oligo`mers i
protoﬁbril·les) so´n les responsables dels de`ﬁcits cognitius i de la mort neuronal que s’observa
en la MA.
6.2 Agregacio´ de βA
6.2.1 Caracteritzacio´ biof´ısica
L’estudi dels agregats de βA presenta diﬁcultats importants, degut al fet que les espe`cies in-
terme`dies so´n dina`miques i metaestables. E´s per aixo` que els cient´ıﬁcs han tractar d’estudiar
els oligo`mers de βA estabilitzant-los en determinades condicions. La manca d’informacio´ es-
tructural i de caracteritzacio´ dels diferents estadis de l’agregacio´ de βA van fer-nos decidir
a estudiar aquest proce´s utilitzant la te`cnica de bescanvi proto´/deuteri per marcatge per
pols (PL-HDX, de l’angle`s pulse-labeling hydrogen/deuterium exchange). Aquesta te`cnica
consisteix en dissoldre βA en una solucio´ tampo´ protonada i, a diferents temps d’agregacio´,
Δtagg, bescanviar el tampo´ per aigua deuterada en un interval curt (un pols) de temps,
Δtlabel (temps de marcatge, label en angle`s). Δtlabel s’agafa de manera que els protons
amides exposats de βA es bescanvien, mentre que aquells que no so´n accessibles al dissol-
vent, perque` formen part d’una estructura me´s compacta no so´n bescanviats. El bescanvi
s’atura congelant la mostra amb nitrogen l´ıquid i lioﬁlitzant. Aquestes mostres posterior-
ment es dissolen en una dissolucio´ de DMSO, que mante´ el contingut de deuteri, i s’analitzen
per espectrometria de masses (EM) d’ionitzacio´ per electrospray. L’EM de la capacitat de
detectar i caracteritzar poblacions de mole`cules amb diferents graus de bescanvi, de man-
era que detecta les diverses espe`cies presents en un estadi d’agregacio´ determinat. Aquesta
metodologia permet la deteccio´ i caracteritzacio´ de les espe`cies dina`miques i metaestables
presents en l’agregacio´ de βA.
A l’hora d’estudiar l’agregacio´ de βA, vam decidir caracteritzar els processos d’agregacio´ de
βA40, βA42 i tambe´ de E22Δ-βA42. Aquesta darrera variant e´s una mutacio´ de la prote¨ına
βA42 on falta l’a`cid gluta`mic a la posicio´ 22, trobada en pedigr´ıs japonesos i caracteritzada,
en primera insta`ncia, per formar oligo`mers pero` no ﬁbril·les amiloides. Estudis posteriors,
tanmateix, van demostrar que E22Δ-βA42 tambe´ formava ﬁbril·les amiloides.
En primer lloc vam estudiar l’agregacio´ d’aquestes tres prote¨ınes amb diversos me`todes tradi-
cionals. L’assaig de Tioﬂavina T (ThT) mesura la quantitat de ﬁbril·les amiloides presents en
solucio´. La prote¨ına βA40 es troba en forma ﬁbril·lar despre´s de 19 dies d’agregacio´, mentre
que la prote¨ına βA42 forma ﬁbril·les despre´s de 9 dies d’agregacio´. Tambe´ vam caracteritzar
l’agregacio´ de les variants de βA mitjanc¸ant microscopia de transmissio´ electro`nica (MTE),
una te`cnica que permet estudiar la morfologia dels diferents agregats de βA. Vam observar
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que la prote¨ına βA40 necessitava 17 dies per a formar ﬁbril·les ben deﬁnides, mentre βA42
en necessitava 9. E´s important fer notar que tant en l’agregacio´ de βA40 com en la de βA42
vam detectar intermedis protoﬁbril·lars (ﬁlaments petits, curts i curvilinis d’uns 200 nm).
En la prote¨ına E22Δ-βA42 vam observar protoﬁbril·les i ﬁbril·les des dels primers instants
d’agregacio´. Despre´s de 2 dies, la majoria de prote¨ına es trobava en forma ﬁbril·lar.
Les ﬁbril·les formades pels variants de βA van ser caracteritzades utilitzant difraccio´ de
raigs X. Malgrat no vam ser capac¸os d’alinear les ﬁbril·les, vam poder obtenir patrons de
difraccio´ que ens permeteren quantiﬁcar les dista`ncies intramoleculars i intermoleculars entre
les diferents strands de les ﬁbril·les. En el cas de βA40 i de βA42 vam obtenir valors
ide`ntics: 10.4 i 4.7 A˚, mentre que per E22Δ-βA42 la dista`ncia intramolecular va resultar ser
lleugerament me´s curta: 10.1 A˚.
Malgrat obtenir informacio´ important mitjanc¸ant les tres te`cniques comentades anterior-
ment, cap d’elles ens permeten obtenir informacio´ estructural dels intermedis d’agregacio´
de la prote¨ına βA. Per aixo` vam estudiar els tres variants de βA amb la te`cnica introdu¨ıda
anteriorment: el PL-HDX acoblat a l’EM.
Per tal de poder treballar amb aquesta metodologia del PL-HDX vam haver de desenvolupar
un sistema experimental que ens permete´s desalar les mostres i que alhora fos resistent al
DMSO. Ho vam aconseguir utilitzant cablejat, unions i va`lvules de Teﬂo´ i mantentint els
dissolvents i el sistema de va`lvules a baixa temperatura amb gel. El valor o`ptim de voltage
capil·lar per a evitar adductes en els pics dels espectres de masses va resultar e´sser de 4 kV.
Tambe´ fou molt rellevant de cara a la realitzacio´ experimental de la tesi la descoberta del
bescanvi proto´-deuteri entre diferents mostres en el proce´s de lioﬁlitzacio´. Per tal d’assegurar-
nos una correcta lioﬁlitzacio´ i per mantenir la informacio´ del bescanvi, resulta` clau dur a
terme les lioﬁlitzacions en un lioﬁlitzador propi, sense cap altra mostra processant-se fora de
la d’intere`s.
Amb les condicions d’EM optimitzades, vam dur a terme els experiments de PL-HDX acoblat
a l’EM per a les tres variants de βA. En tots tres casos els espectres de masses segueixen un
patro´ similar: en els estadis inicials, la prote¨ına βA te´ una massa me´s gran que al ﬁnal de
l’agregacio´. Aixo` e´s degut al fet que βA es troba primer en una forma molt poc agregada,
i per tant te´ molt poques amides exposades que puguin bescanviar, mentre que despre´s de
diversos dies d’agregacio´, βA forma estructures me´s compactes on el bescanvi HD e´s me´s
petit.
Per tal d’obtenir me´s informacio´ de l’experiment de PL-HDX, vam ajustar globalment els
espectres per les diferents prote¨ınes a una combinacio´ de corbes gaussianes. Cada corba
gaussiana representa una espe`cie diferent present en l’agregacio´ de βA. Per cada prote¨ına,
tots els espectres de massa corresponents foren ajustats a un nombre de gaussianes deﬁnit:
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3 en el cas de βA40 i βA42, i 2 en el cas d’E22Δ-βA42.
En el cas de βA40, la primera espe`cie detectada es corresponia en massa amb la prote¨ına amb
totes les amides exposades, indicant que aquesta espe`cie inclou mono`mer i/o agregats sense
proteccio´ contra HDX. La poblacio´ relativa d’aquesta primera espe`cie decreix gradualment
des de 0 a 17 dies. Les protoﬁbril·les de βA40 foren les segones espe`cies detectades, correspo-
nent a masses de 25.1 ± 1.0 amides exposades. Basant-nos en l’amplada de banda associada
a les protoﬁbril·les de βA40, aquesta va resultar ser l’espe`cie me´s heteroge`nia formada du-
rant l’agregacio´, essent la seva prese`ncia constant pero` ma`xima als 13 dies d’agregacio´. La
darrera espe`cie detectada corresponia a masses de 13.5 ± 0.6 amides exposades. La seva
poblacio´ es correlacionava amb la senyal de ThT i l’observacio´ de ﬁbril·les ben deﬁnides per
MTE; aquesta espe`cie la vam assignar a ﬁbril·les.
L’agregacio´ de βA42 tambe´ fou estudiada amb l’estrate`gia de PL-HDX. Malgrat el nombre
d’espe`cies trobades per βA40 i βA42 fou el mateix, els nostres experiments varen demostrar
que la naturalesa dels agregats primerencs e´s diferent per les dues prote¨ınes. Els correspo-
nents a βA42 mostraren un grau de proteccio´ me´s elevat que en βA40: 32.8 ± 0.8 (de 41)
vs 37.4 ± 0.5 (de 39) per βA40. Aquests resultats so´n consistents amb la tende`ncia superior
a agregar per part de βA42. La tercera poblacio´ detectada la vam assignar, com en el cas
de βA40, a ﬁbril·les amiloides, mentre que l’espe`cie interme`dia, amb 23.6 ± 1.8 amides ex-
posades, resulta` ser l’espe`cie detectada me´s heteroge`nia. Quan aquesta espe`cie e´s ma`xima
en l’agregacio´, les imatges de MTE mostren clarament protoﬁbril·les abundants, pel que vam
assignar aquesta segona poblacio´ de βA42 a protoﬁbril·les.
Finalment, l’experiment de PL-HDX tambe´ el vam aplicar a l’estudi d’E22Δ-βA42. Vam
detectar dues espe`cies: protoﬁbril·les, que mostraren un nombre d’amides exposades superior
al mono`mer d’E22Δ-βA42 (30.8 ± 0.3 de 41) i ﬁbril·les. La quantitat de protoﬁbril·les
en el cas d’E22Δ-βA42 decreix ra`pidament en els estadis inicials i la poblacio´ de ﬁbril·les
incrementa. Aquests experiments tambe´ mostren una evide`ncia me´s de l’alta tende`ncia a
agregar d’aquesta prote¨ına.
6.2.2 Estudis de toxicitat
L’experiment de PL-HDX ens va permetre caracteritzar, detectar i quantiﬁcar les diferents
espe`cies conformant l’agregacio´ de βA. Aquesta descoberta obre la possibilitat de mesurar
la contribucio´ de cada espe`cie a una variable determinada. Com que βA esta` relacionada
amb la neurotoxicitat en la MA, vam estudiar la inﬂue`ncia dels agregats de βA en cultius
primaris de neurones d’hipocamp de ratolins.
Per posar a punt els experiments de neurotoxicitat vam utilitzar l’assaig de bromur de 3-(4,5-
dimetilthiazol-2-il)-2,5-dipheniltetrazole (MTT) i vam treballar amb els oligo`mers sinte`tics
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de βA42 coneguts com a ADDLs. Vam trobar que les condicions o`ptimes per a determinar
la toxicitat d’Aβ en cultius primaris neuronals eren treballar a una concentracio´ de 5 μM
de βA i incubar les mostres en els cultius durant 24 hores. En aquests assaigs previs tambe´
vam determinar que el nostre tampo´ d’agregacio´ presentava certa toxicitat pero` no impedia
fer les mesures que nosaltres vol´ıem dur a terme.
Tambe´ fou rellevant per a l’estudi de toxicitat determinar mitjanc¸ant l’experiment de PL-
HDX acoblat a EM el fet que els agregats de βA conservaven l’estructura despre´s d’haver
estat congelats a -20◦C i descongelats. Aquesta observacio´ fou important ja que vam fer els
assaigs de toxicitat en paral·lel el mateix dia, utilitzant els mateixos cultius primaris.
En aquests experiments de neurotoxicitat vam utilitzar un conjunt de mostres ide`ntiques a
les usades pels experiments de PL-HDX i vam mesurar la supervive`ncia dels cultius primaris
mitjanc¸ant l’assaig d’MTT. En el cas de βA40, la supervive`ncia neuronal va decre´ixer des
d’un 90% a una toxicitat ma`xima de 65% als 17 dies. La viabilitat s’incrementa` ﬁns a un
80% al cap de 24 dies. Per a un Δtagg donat, vam combinar les poblacions obtingudes per
EM amb els resultats d’MTT i vam usar una regressio´ multilineal per a obtenir la toxicitat
de les diferents espe`cies: 101 ± 12 pels agregats primerencs, 56 ± 13 per les protoﬁbril·les
de βA40 i 78 ± 7 per les ﬁbril·les.
Quan els mateixos experiments es dugueren a terme amb preparacions de βA42, vam observar
un patro´ similar que en el cas de βA40, malgrat la relacio´ entre protoﬁbril·les de βA42 i
neurotoxicitat resulta` ser molt me´s signiﬁcativa. Els temps inicials d’agregacio´ en βA42
mostraren una toxicitat superior que en βA40 (comenc¸ant per un 80% de viabilitat a dia
0) i la viabilitat decreixe´ gradualment ﬁns a un ma`xim de 38% als 7 dies d’agregacio´. La
viabilitat tornava a pujar ﬁns arribar al mateix valor que al principi, 80%, al cap d’11 dies.
Combinant aquestes dades amb les obtingudes en l’experiment de PL-HDX vam obtenir els
segu¨ents valors de toxicitat per les diferents espe`cies de βA42: 74 ± 7 pels estadis d’agregacio´
primerencs, 17 ± 10 per les protoﬁbril·les i 106 ± 12 per les ﬁbril·les. Malgrat les quantitats
relatives de protoﬁbril·les en βA40 i βA42 so´n similars, les protoﬁbril·les de βA42 mostraren
una neurotoxicitat superior i una correlacio´ me´s gran amb la toxicitat global mesurada.
En el cas d’E22Δ-βA42 no vam observar toxicitat en les preparacions i, per tant, no vam
poder determinar la toxicitat corresponent a les espe`cies conformant el proce´s d’agregacio´
d’E22Δ-βA42.
6.2.3 Discussio´
Amb l’experiment de PL-HDX hem estat capac¸os d’identiﬁcar les diferents espe`cies presents
en el proce´s d’agregacio´ de tres variants de la prote¨ına βA: βA40, βA42 i E22Δ-βA42.
Malgrat vam detectar el mateix nombre d’espe`cies per βA40 i βA42, les dades obtingudes
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demostren que hi ha difere`ncies estructurals entre ells. El nombre diferent d’amides ex-
posades en els agregats primerencs de les dues prote¨ınes e´s consistent amb la tende`ncia me´s
gran a agregar de βA42. A me´s, malgrat les protoﬁbril·les per βA40 i βA42 mostraren tambe´
un nombre similar d’amides exposades, les protoﬁbril·les de βA42 mostraren ser molt me´s
to`xiques que per βA40, consistent amb la major toxicitat de la prote¨ına βA42. Aquestes
difere`ncies poden ser explicades pel fet que els dos aminoa`cids extra en βA42 confereixen
una hidrofobicitat superior que implica una major tende`ncia a l’agregacio´ i una interaccio´
me´s forta amb membranes cel·luars que porta a una major toxicitat. Tambe´ cal tenir en
compte que el comportament de la prote¨ına E22Δ-βA42 que hem observat esta` d’acord amb
treballs anteriors, en que` es mostrava que aquesta prote¨ına agregava molt ra`pidament.
El fet de detectar tres espe`cies amb estructures diferents, aix´ı com la seva evolucio´ en
funcio´ del temps, esta` d’acord amb el mecanisme de formacio´ amiloide anomenat conversio´n
conformacional nucleada. Aquest mecanisme proposa que les mono`mers o els agregates
primerencs poc estructurats progressen vers estructures protoﬁbril·lars, que so´n capaces en-
cara d’evolucionar en estructures ﬁbril·lars me´s r´ıgides.
En deﬁnitiva, hem detectat diferents agregats presents durant l’agregacio´ de βA utilitzant
l’experiment de PL-HDX acoblat a EM. Mitjanc¸ant estudis paral·lels de neurotoxicitat hem
estat capac¸os de determinar que les protoﬁbril·les, provinents d’un reordenament estrucutral,
so´n les espe`cies me´s to`xiques per les neurones. Aix´ı doncs, el nostre treball apunta vers
l’establiment de determinants estructurals de la neurotoxicitat de les protoﬁbril·les de βA
a me´s de ser un punt de partida pel desenvolupament d’estrate`gies terape`utiques contra la
MA.
6.3 Avaluacio´ de petites mole`cules
6.3.1 Assaig d’una biblioteca de mole`cules interferint l’agregacio´
de βA
S’han dut a terme molts estudis en els quals diversos composts mostren la capacitat d’incrementar
o inhibir l’agregacio´ de βA. Tanmateix, la majoria d’aquests no do´na informacio´ detallada
en el mecanisme d’accio´ d’aquestes mole`cules i, per tant, es desconeix el tipus d’agregat amb
que aquestes mole`cules interactuen o estabilitzen.
Per tal d’aportar informacio´ en aquest camp, vam provar l’efecte d’una petita biblioteca de
compostos en l’agregacio´ de la prote¨ına βA42, ja que e´s aquesta la que esta` me´s associada
amb l’etiologia de la MA. Aquesta biblioteca consistia de 20 mole`cules amb diferents carac-
ter´ıstiques qu´ımiques i els compostos que la formaven complien almenys un de les segu¨ents
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premises: 1) estar o haver estat en fases cl´ıniques contra la MA, 2) inhibir la ﬁbril·lacio´ de
βA estabilitzant oligo`mers de βA in vitro, 3) retardar la formacio´ de ﬁbril·les de βA, i 4)
inhibir la formacio´ d’oligo`mers pero` no de ﬁbril·les de βA.
Per tal de dur a terme un primer proce´s de seleccio´, vam utilitzar un procediment anomenat
assaig de retencio´ en ﬁltre (ARF). Aquest experiment proporciona una manera de determinar
l’efecte de compostos en la formacio´ d’agregats de βA estables en dodecilsulfat de sodi
(SDS, de l’angle`s sodium dodecyl sulfate). Utilitzant l’ARF, els agregats d’alt pes molecular,
resistents a l’SDS queden retinguts en una membrana, mentre que la prote¨ına monome`rica
i els agregats petits i solubles passen a trave´s d’ella. La quantitat d’agregats resistents a
SDS es poden quantiﬁcar per immunodeteccio´ amb l’antico`s monoclonal 6E10, que reconeix
espec´ıﬁcament la part N-terminal de βA.
Vam seguir l’agregacio´ de βA42 en abse`ncia i en prese`ncia de les mole`cules de la nostra
biblioteca per l’ARF. L’agregacio´ de βA42 en abse`ncia de composts tambe´ la vam mesurar
amb l’assaig de ThT. Aixo` ens va permetre identiﬁcar els agregats resistents a SDS amb les
ﬁbril·les de βA42. La majoria de les mole`cules (15 de 20) que vam provar acceleraren la
formacio´ d’agregats resistents a SDS. Tres mole`cules mostraren no tenir un efecte clar en
l’agregacio´ de βA42, mentre que dues mole`cules inhibiren la formacio´ d’agregats resistents
a SDS.
Basant-nos en aquests resultats obtinguts per l’ARF, vam seleccionar un nombre petit
pero` representatiu de composts per a e´sser estudiats pel me`tode del PL-HDX acoblat a
EM. Les mole`cules que vam triar foren l’entacapona (Ent) i la diamida de dialliltartrat
(DATD, de l’angle`s) com a compostos representatius accelerant l’agregacio´ de βA42, la 2,2’-
dihidroxibenzofenona (DHB) com a mole`cula sense efecte en l’agregacio´ de βA42, i tambe´ el
gal·lat d’epigal·locatequina (EGCG, de l’angle`s) i el pe`ptide inrD com a compostos inhibint
l’agregacio´ de βA42.
6.3.2 Estudi per PL-HDX de l’efecte de 5 mole`cules en l’agregacio´
de βA
Aix´ı doncs, vam dur a terme experiments d’agregacio´ de βA42 en abse`ncia i prese`ncia de les 5
mole`cules anteriorment mencionades durant 12 dies, i vam aplicar l’experiment de PL-HDX
acoblat a EM.
Quan βA42 agregava en prese`ncia de l’Ent o de la DATD vam detectar tres espe`cies. Aquestes
no mostraven difere`ncies signiﬁcatives en quant a amides exposades o heterogene¨ıtat amb
βA42 control, pero` la formacio´ de l’espe`cie ﬁbril·lar es formava molt me´s ra`pidament, mentre
que els agregats primerencs deixaven d’estar presents en solucio´ als 2 dies d’agregacio´. Aix´ı
doncs, aquestes dues mole`cules acceleraven la cine`tica de formacio´ de ﬁbril·les de βA42.
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Quan vam aplicar l’experiment de PL-HDX a βA42 + DHB, vam descobrir que aquesta
mole`cula involucrava la formacio´ de tres espe`cies diferents. Com en els casos anteriors,
les caracter´ıstiques de proteccio´ i homogene¨ıtat no diferien signiﬁcativament de βA42 con-
trol, pero` la DHB tenia una inﬂue`ncia siginiﬁcativa en l’espe`cie protoﬁbril·lar. Malgrat els
agregats primerencs desapareixien ra`pidament durant l’agregacio´, era la poblacio´ de protoﬁb-
ril·les la que augmentava signiﬁcativament, i no les ﬁbril·les. La DHB promovia la formacio´
i estabilitzacio´ de protoﬁbril·les, pero` no ﬁbril·les de βA42.
En el cas de l’agregacio´ de βA42 en prese`ncia del pe`ptid inrD, els experiments de PL-HDX
van demostrar que nome´s dues espe`cies es formaven. En determinar el nombre d’amides
exposades i la heterogene¨ıtat de les dues espe`cies formades, vam poder concloure que en el
temps que durava l’experiment, el pe`ptid inrD inhibia la formacio´ de ﬁbril·les, estabilitzant
l’espe`cie oligome`rica protoﬁbril·lar.
Quan vam aplicar l’experiment de PL-HDX per estudiar l’agregacio´ de βA42 en prese`ncia
d’EGCG, vam obtenir uns espectres de masses complexos: vam observar valors d’m/z me´s
grans que els que esperar´ıem per βA42 totalment deuterada (bescanviada). A me´s, la relacio´
senyal soroll per l’espectra era pitjor en incrementar Δtagg. Aquests resultats inesperats
van fer que dugue´ssim a terme l’experiment de PL-HDX en les mateixes mostres i temps
d’agregacio´ pero` sense canviar la solucio´ protonada a aigua deuterada. Aix´ı, tots els espec-
tres obtinguts haurien de mostrar un u´nic pic corresponent a βA42 totalment protonada.
Tanmateix, vam observar un segon pic corresponent a una massa superior a βA42 en 16 uma.
A me´s, la intensitat d’aquest segon pic incrementava a temps d’agregacio´ me´s llargs. Basant-
nos en aquest increment en massa i l’ana`lisi d’aquestes mostres per ressona`ncia magne`tica
nuclear (RMN), vam assignar aquest segon pic a una forma oxidada de βA42 en la qual el
grup sulfur de la metionina 35 era oxidat a grup sulfo`xid. Aix´ı doncs, en prese`ncia d’EGCG,
la prote¨ına βA42 sofria una modiﬁcacio´ qu´ımica.
6.3.3 Discussio´
Aplicar la metodologia de PL-HDX ha resultat ser molt u´til per tal d’obtenir informacio´
rellevant sobre el mecanisme d’accio´ de 5 mole`cules en l’agregacio´ de βA42. Aquestes com-
postos van ser escollides gra`cies al me`tode d’ARF, molt u´til per a seleccionar candidats per
a un posterior estudi me´s detallat.
Tant l’Ent com la DATD van resultar ser mole`cules accelerant l’agregacio´ de βA42. Aquest
comportament e´s diferent del descrit pre`viament per aquestes mole`cules. En treball del grup
del Dr. Lashuel, l’Ent inhibeix l’agregacio´ de βA42. Aquest comportament e´s derivat d’un
estudi de βA42 + Ent amb l’assaig de ThT i per MTE. L’assaig de ThT no esta` recomanat
per a estudiar l’agregacio´ en prese`ncia de mole`cules, ja que la mole`cula pot interaccionar
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amb la ﬂuoresce`ncia de ThT i, per tant, donar resultats erronis. A me´s, no trobar ﬁbril·les
amiloides en un reixeta de MTE no elimina la possibilitat que de fet les ﬁbril·les amiloides
estiguin presents en solucio´ pero` no s’hagin dipositat be´ en la reixeta per la interaccio´ de la
mole`cula.
En el cas de la DATD, el grup del Dr. Glabe va establir que formava oligo`mers de βA42 pero`
no ﬁbril·les. Tanmateix, l’evide`ncia nome´s prove´ d’estudis d’immunoreactivitat dels agregats
formats per la DATD i βA42 contra l’antico`s A11, un antico`s que reconeix espec´ıﬁcament
oligo`mers. A me´s, l’article en qu¨estio´ no mostra en cap moment dades experimentals en el
cas de la DATD, fent dif´ıcil l’assignacio´ d’una funcio´ espec´ıﬁca a la DATD. Nosaltres vam
trobar que la DATD accelerava la ﬁbril·lacio´ de βA42. Ja que els agregats primerencs i les
protoﬁbril·les coexisteixen amb les ﬁbril·les, aquestes mostres podrien ser positives davant
l’A11, explicant el resultats del Dr. Glabe i col·laboradors.
L’ARF va mostrar que la DHB tenia un efecte negligible en βA42. Amb la te`cnica del
PL-HDX vam demostrar que la DHB inﬂu¨ıa signiﬁcativament en l’agregacio´ de βA42 pro-
movent la formacio´ d’espe`cies protoﬁbril·lars, un agregat no detectable per l’ARF. El grup
del Dr. Glabe va estblir que DHB inhibia l’oligomeritzacio´ i la ﬁbril·lacio´ de βA42. Com
en el cas de la DATD, aquest resultats s’obtingueren amb l’u´s de l’antico`s A11. Nosaltres
vam establir que la DHB inhibia la formacio´ de ﬁbril·les pero` no vam trobar que inhib´ıs la
formacio´ d’oligo`mers, sino´ me´s aviat al contrari. Aquests resultats so´n fa`cilment explicables
si l’oligo`mer estabilitzat per la DHB no e´s positiu contra l’A11.
El pe`ptid inrD, desenvolupat en el nostre laboratori, inhibia la ﬁbril·lacio´ de βA42 retardant
la formacio´ de ﬁbril·les. Amb l’experiment de PL-HDX vam demostrar que l’inrD prevenia la
formacio´ de la poblacio´ ﬁbril·lar i estabilitzava l’oligo`mer protoﬁbril·lar, inhibint l’agregacio´
de βA42. Aquesta informacio´ complementa el que ja esta` descrit i en proporciona de nova
sobre el mecanisme d’accio´ d’aquest pe`ptid: l’inrD estabilitza els agregats primerencs i les
protoﬁbril·les en funcio´ del temps. Aquest inhibidor podria ser un candidat a estudis poste-
riors en la cerca d’agents terape`utics antiamiloidoge`nics.
En treballs previs es va descriure com l’EGCG formava agregats de βA42 que no eren to`xics.
Tambe´ es descrigue´ la capacitat d’aquesta mole`cula per a disgregar ﬁbril·les amiloides. Un
estudi recent dona` nova informacio´ en el mecanisme de disgregacio´ de ﬁbril·les amiloides per
l’EGCG: la forma oxidada de l’EGCG interaccionava covalentment amb els grups amino de
les prote¨ınes. A me´s, diversos estudis han determinat el rol important que te´ la metionina
35 en l’agregacio´ de βA.
Amb els nostres estudis establim una nova connexio´ entre modiﬁcacions qu´ımiques de βA i
la inhibicio´ per mole`cules petites amb un efecte global en l’agregacio´ de βA. Amb els nostres
resultats d’EM i de RMN, hem pogut determinar que l’EGCG modiﬁca covalentment la
prote¨ına βA42. El grup sulfur en la metionina 35 e´s oxidat a sulfona, probablement com
a consequ¨e`ncia de la prese`ncia d’EGCG oxidada que alhora oxida βA42 en el lloc me´s
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susceptible de ser-ho, en la metionina 35. En trobar diﬁcultats en ionitzar la mostra per
l’estudi d’EM a temps llargs d’agregacio´, vam suposar que aquests agregats de βA42 so´n
units covalentment quan l’agregacio´ te´ lloc, ja que la dissolucio´ de DMSO que utilitzem per
EM e´s capac¸ de trencar tambe´ els agregats ﬁbril·lars. Aquesta reaccio´ covalent podria tenir
lloc com s’ha descrit, per mitja` dels grups amino de les prote¨ınes. Combinant els nostres
resultats amb els obtinguts pre`viament per d’altres, vam ser capac¸os d’explicar l’oxidacio´ de
βA42, la seva agregacio´ i la seva unio´ covalent amb l’EGCG.
Com a conclusio´, l’experiment de PL-HDX ha resultat e´sser una te`cnica potent per a detec-
tar, caracteritzar i quantiﬁcar les espe`cies formades en l’agregacio´ de βA42 modulada per
mole`cules, una manera de distingir entre els efectes diferents que tenen diversos compostos,
i una eina per a aprofundir en el mecanisme d’accio´ de mole`cules interaccionant amb βA42.
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